Document:

Form of Amended and Restated Change of Control Agreement

 Exhibit 10.2 

 

			
	 Name
	  	 Title

	Colin Broom M.D.	  	Vice President, Chief Scientific Officer
		
	Thomas F. Doyle	  	Vice President, General Counsel and Secretary
		
	Vincent J. Milano	  	President, Chief Executive Officer
		
	Daniel Soland	  	Vice President, Chief Operating Officer
		
	Robert Pietrusko	  	Vice President, Global Regulatory Affairs and Quality
		
	 Charles Rowland
  

Clayton Fletcher
  
 Peter Wolf
	  	 Vice President, Chief Financial Officer
  

Vice President, Business Development
  

Vice President, General Counsel

 CHANGE OF CONTROL AGREEMENT 
 THIS CHANGE OF CONTROL AGREEMENT (this
“Agreement”), is made on this 6th day of January, 2010, by and between VIROPHARMA INCORPORATED (the “Company”) and (the “Employee”). 

WHEREAS, the Employee serves as an employee of the Company; and 
 WHEREAS, the Company desires to establish certain protections for the Employee in the event of the Employee’s termination of employment under the circumstances described herein. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained herein, and intending to be bound
hereby, the parties agree as follows: 
 SECTION 1 Definitions. As used herein: 

1.1. “Base Salary” means, as of any given date, the annual base rate of salary payable to the Employee by the Company,
as then in effect; provided, however, that in the case of a resignation by the Employee for the Good Reason described in Section 1.7.3, “Base Salary” will mean the annual base rate of salary payable to the Employee by the
Company, as in effect immediately prior to the reduction giving rise to the Good Reason. 
 1.2. “Board” means
the Board of Directors of the Company. 
 1.3. “Cause” means fraud, embezzlement, or any other criminal conduct
that adversely affects the Company, committed intentionally by the Employee in connection with the Employee’s employment by the Company, or the Employee’s conviction of, or plea of guilty or nolo contendere to, any felony.

 1.4. “Change of Control” has the same meaning ascribed to such term under the Amended and Restated 2005
Equity Incentive Plan. 

 1.5. “Code” means Internal Revenue Code of 1986, as amended. 

1.6. “Disability” means a condition entitling the Employee to benefits under the Company’s long term disability
plan, policy or arrangement; provided, however, that if no such plan, policy or arrangement is then maintained by the Company and applicable to the Employee, “Disability” will mean the Employee’s inability, by reason of any
physical or mental impairment, to substantially perform the Employee’s regular duties to the Company, as determined by the Board in its sole discretion (after affording the Employee the opportunity to present the Employee’s case), which
inability is reasonably contemplated to continue for at least one year from its commencement and at least ninety (90) days from the date of such determination. 
 1.7. “Good Reason” means, without the Employee’s prior written consent, any of the following: 
 1.7.1. a material diminution in the Employee’s authorities, duties, titles or responsibilities; 
 1.7.2. the location of the facility at which the Employee is required to perform his or her duties is more than fifty (50) miles from Exton, Pennsylvania; 

1.7.3. a reduction of the Employee’s Base Salary or the amount of the Employee’s Target Bonus of five percent (5%) or
more; 
 1.7.4. the Company’s failure to pay or make available any material payment or benefit due under this Agreement or
any other material breach by the Company of this Agreement. 
 However, the foregoing events or conditions will constitute Good Reason only if
(A) such event or condition occurs during the period beginning ninety (90) days immediately preceding a Change of Control and ending twenty-four (24) months thereafter and (B) the Employee provides the Company with written
objection to the event or condition within sixty (60) days following the occurrence thereof, the Company does not reverse or otherwise cure the event or condition within thirty (30) days of receiving that written objection and the Employee
resigns the Employee’s employment within ninety (90) days following the expiration of that cure period. 
 1.8.
“Release” means a release substantially identical to the one attached hereto as Exhibit A. 
 1.9.
“Target Bonus” means, with respect to any year, 100% of the target amount of the Employee’s annual bonus opportunity, expressed as a percentage of Base Salary, that would be payable to the Employee with respect to that year,
whether under an employment or incentive agreement, under any bonus plan or policy of the Company or otherwise, assuming that all applicable performance goals are met and conditions to the payment of such bonus are satisfied. 

  
 2 

 SECTION 2 Certain Terminations Following a Change of Control. 

2.1. Severance Events Following a Change of Control. If the Employee’s employment with the Company ceases within the
twenty-four (24) month period following the date of a Change of Control as a result of a termination by the Company without Cause, a resignation by the Employee for Good Reason or due to the Employee’s death or Disability, then, subject to
Section 3 and Section 5, the Employee will be entitled to the following: 
 2.1.1. (i) any Base Salary earned through
the effective date of termination that remains unpaid, with any such amounts paid on the first regularly scheduled payroll date following the effective date of termination; (ii) any bonus payable with respect to any fiscal year which ended
prior to the effective date of the Employee’s termination of employment, which remains unpaid, with such amount paid in the first regularly scheduled payroll date following the effective date of termination or, if later, at the same time the
bonus would have otherwise been payable to the Employee; and (iii) any reimbursement or payment due to the Employee on or prior to the date of such termination which remains unpaid to the Employee, with any such payment being made promptly
following the effective date of termination (collectively, the “Accrued Obligations”); 
 2.1.2. a lump sum
cash payment equal to 200% of the Employee’s Base Salary as in effect on such date (without taking into effect any reduction described in Section 1.7.3 above); 
 2.1.3. a lump sum cash payment equal to two (2) times his annual Target Bonus as in effect on such date; and 
 2.1.4. provided that the Employee is eligible for, and timely elects, COBRA continuation coverage, for a period of eighteen (18) months commencing from the date of the Employee’s termination of
employment, the Company will reimburse the Employee for the monthly COBRA cost of continued coverage for the Employee, and, where applicable, his spouse and eligible dependents, paid by the Employee under the Company’s group health plan
pursuant to section 4980B of the Code, less the amount that the Employee would be required to contribute for such coverage if the Employee were an active employee of the Company. These payments will commence within 30 days following the termination
date and will be paid on the first payroll date of each month. 
 2.2. Severance Events Preceding a Change of Control. If
the Employee’s employment with the Company ceases during the ninety (90) days immediately preceding the date of a Change of Control as a result of a termination by the Company without Cause, a resignation by the Employee for Good Reason or
due to the Employee’s death or Disability, then, subject to Section 3 and Section 5, the Employee will be entitled to the following: 
 2.2.1. the Accrued Obligations; 
 2.2.2. the Company will make a lump sum cash
payment to the Employee equal to 200% of the Employee’s Base Salary as in effect on such date (without taking into effect any reduction described in Section 1.7.3 above); 

2.2.3. a lump sum cash payment equal to two (2) times his annual Target Bonus as in effect on such date; and 

  
 3 

 2.2.4. provided that the Employee is eligible for, and timely elects, COBRA continuation
coverage, for a period of eighteen (18) months commencing from the date of the Employee’s termination of employment, the Company will reimburse the Employee for the cost of the applicable monthly COBRA premium for the Employee, and, where
applicable, his spouse and eligible dependents, paid by the Employee under the Company’s group health plan pursuant to section 4980B of the Code, less the amount that the Employee would be required to contribute for such coverage if the
Employee were an active employee of the Company. These payments will commence within thirty (30) days following the termination date and will be paid on the first payroll date of each month. If applicable, the Employee will be reimbursed for
COBRA premiums paid out-of-pocket for the period following the Employee’s termination date through the date of the Change of Control in an amount equal to the portion of the premium amount paid by the Company toward the applicable premium under
its group health plan for active employees during the Employee’s term of employment with the Company; provided that if the Employee or the Employee’s spouse or eligible dependents, as applicable, have not elected (and is no longer
eligible to elect) COBRA continuation coverage, no waiver or reimbursement will be made pursuant to this Section 2.2.3. 
 Notwithstanding
the foregoing, if the Company’s obligation to make the payments provided for in Sections 2.1.2, 2.1.3 or Section 2.2.2 and 2.2.3 arises due to the Employee’s death or Disability, the cash payments described in Sections 2.1.2, 2.1.3,
2.2.2 and 2.2.3 will be reduced by the amount of benefits paid or payable to the Employee (or the Employee’s representative(s), heirs, estate or beneficiaries) pursuant to the life insurance or disability plans, policies or arrangements of the
Company by virtue of the Employee’s death or Disability (including, for this purpose, only that portion of such life insurance or disability benefits funded solely by the Company or by premium payments made by the Company and not including the
portion of such benefits paid for by the Employee). The payments and benefits described in this Section are in lieu of (and not in addition to) any other severance plan, fund, agreement or other arrangement maintained by the Company. 

SECTION 3 Timing of Payments Following Termination. Notwithstanding any provision of this Agreement, the payments and benefits
described in Section 2 (other than any Accrued Obligations) are conditioned on the Employee’s execution and delivery to the Company of the Release in a manner consistent with applicable law. The amounts described in Sections 2.1.2, 2.1.3
or Section 2.2.2 and 2.2.3 (as applicable) will be paid in a lump sum, within sixty (60) days following execution and nonrevocation of the Release. Notwithstanding any provision of this Agreement to the contrary, in no event shall the
timing of the Employee’s execution of the Release, directly or indirectly, result in the Employee designating the calendar year of payment, and if a payment that is subject to execution of the Release could be made in more than one taxable
year, payment shall be made in the later taxable year. 
 SECTION 4 Parachute Payments. 

4.1. The payments and benefits provided under Section 2 shall be made without regard to whether such payments and benefits, either
alone or in conjunction with any other payments or benefits made available to the Employee by the Company and its affiliates, will result in the Employee being subject to an excise tax under Section 4999 of the Code (the “Excise
Tax”) or whether the deductibility of such payments and benefits would be limited or 

  
 4 

 
precluded by Section 280G of the Code; provided, however, that if the Total After-Tax Payments (as defined below) would be increased by limitation or elimination of payments or
benefits provided under Section 2, then the amounts and benefits payable under Section 2 will be reduced to the minimum extent necessary to maximize the Total After-Tax Payments. For purposes of this Section 4, “Total
After-Tax Payments” means the total of all “parachute payments” (as that term is defined in Section 280G(b)(2) of the Code) made to or for the benefit of the Employee (whether made under this Agreement or otherwise), after
reduction for all applicable taxes (including, without limitation, the Excise Tax). If a reduction to the payments or benefits provided under Section 2 is required pursuant to this Section 4, such reduction shall occur to the payments and
benefits in the order that results in the greatest economic present value of all payments and benefits actually made to the Employee. 
 4.2. All determinations to be made under this Section 4 shall be made by the Company’s independent public accountant (the “Accounting Firm”) immediately prior to the Change of
Control. In the event that the Accounting Firm is serving as accountant or auditor for the individual, entity or group effecting the Change of Control, the Employee may appoint another nationally recognized public accounting firm to make the
determinations required hereunder (which accounting firm shall then be referred to as the Accounting Firm hereunder). All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any determination by the Accounting Firm shall
be binding upon the Company and the Employee, except as described in the next Section. 
 4.3. As a result of the uncertainty in
the application of Section 280G and Section 4999 of the Code at the time of the Change of Control, it is possible that payments and benefits which will not have been made or provided by the Company should have been made
(“Underpayment”) or payments and benefits are made or provided by the Company which should not have been made (“Overpayment”), consistent with the calculations required to be made hereunder. In the event that there
is a final determination by the Internal Revenue Service, or a final determination by a court of competent jurisdiction, that an Overpayment has been made, any such Overpayment shall repaid to the Company by the Employee within thirty (30) days
of such determination, with interest at the applicable Federal rate provided for in Section 7872(f)(2). In the event that there is a final determination by the Internal Revenue Service, or a final determination by a court of competent
jurisdiction, any such Underpayment shall be promptly paid by the Company to or for the benefit of the Employee together with interest at the applicable Federal rate provided for in Section 7872(f)(2) of the Code, within thirty (30) days
of such determination. 
 4.4. The Employee shall take such action (other than waiving the Employee’s right to any payments
or benefits) as the Company reasonably requests under the circumstances to mitigate or challenge any tax contemplated by this Section 4. If the Company reasonably requests that the Employee take action to mitigate or challenge, or to mitigate
and challenge, any such tax or assessment and the Employee complies with such request, the Company shall provide the Employee with such information and such expert advice and assistance from the Company’s accountants, lawyers and other advisors
as the Employee may reasonably request and shall pay for all expenses incurred in effecting such compliance and any related fines, penalties, interest and other assessments. 

  
 5 

 SECTION 5 Restrictive Covenants. 

5.1. During the period of the Employee’s employment by the Company and, only if the Employee’s employment with the Company
terminates pursuant to Section 2.1 or 2.2 and the Employee begins to receive the payments and benefits provided for under either such Section, for a period of one (1) year beginning on the later of (i) the Employee’s termination
of employment and (ii) the date of a Change of Control (the “Restricted Period”), except with the written consent of the Board, the Employee will not (except in his capacity as an employee of the Company) do any of the
following, directly or indirectly: 
 5.1.1. the Employee shall not directly or indirectly, own, manage, operate, join,
control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, employee, partner, principal, agent, representative, stockholder, consultant, investor or otherwise with, or
use or permit his name to be used in connection with, any person, business or enterprise which directly or indirectly engages in the development, marketing or sale of prescription drug products or compounds that are competitive with: (i) those
products being marketed by the Company at the time of the Employee’s termination; (ii) those products, product candidates or compounds in clinical development or a clinical research program; or (iii) those products, product candidates
or compounds that the Employee was aware were under pre-clinical development by the Company and expected to be in clinical development or in a clinical research program within six (6) months of the Employee’s termination (collectively, the
“Company’s Business”). 
 5.1.2. solicit, entice or induce any customer to become a customer of any other
person, firm or corporation with respect to the Company’s Business or to cease doing business with the Company or its subsidiaries or affiliates, and the Employee will not approach any such person, firm or corporation for such purpose or
authorize or knowingly approve, encourage or assist the taking of such actions by any other person, firm or corporation; or 

5.1.3. solicit, recruit or hire any part-time or full-time employee, representative or consultant of the Company or its subsidiaries or
affiliates to work for a third party other than the Company or its subsidiaries or affiliates, or engage in any activity that would cause any employee, representative or consultant to violate any agreement with the Company or its subsidiaries or
affiliates. The foregoing covenant shall not apply to any person after twelve (12) months have elapsed after the date on which such person’s employment by the Company has terminated. 

5.2. The foregoing restrictions shall not be construed to prohibit the Employee’s ownership of less than five percent of any class
of securities of any corporation which is engaged in any of the foregoing businesses and has a class of securities registered pursuant to the Securities Exchange Act of 1934, as amended, provided that such ownership represents a passive investment
and that neither the Employee nor any group of persons including the Employee in any way, either directly or indirectly, manages or exercises control of any such corporation, guarantees any of its financial obligations, otherwise takes any part in
its business, other than exercising the Employee’s rights as a stockholder, or seeks to do any of the foregoing. 

  
 6 

 5.3. The Employee acknowledges that the restrictions contained in this Section 5 are
reasonable and necessary to protect the legitimate interests of the Company and its affiliates, that the Company would not have entered into this Agreement in the absence of such restrictions, and that any violation of any provision of this Section
will result in irreparable injury to the Company. The Employee further represents and acknowledges that (i) he has been advised by the Company to consult his own legal counsel in respect of this Agreement, and (ii) that he has had full
opportunity, prior to execution of this Agreement, to review thoroughly this Agreement with his counsel. 
 5.4. The Employee
agrees that the Company shall be entitled to preliminary and permanent injunctive relief, without the necessity of proving actual damages, as well as an equitable accounting of all earnings, profits and other benefits arising from any violation of
this Section 5, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled. In the event that any of the provisions of this Section 5 should ever be adjudicated to exceed the time,
geographic, service, or other limitations permitted by applicable law in any jurisdiction, then such provisions shall be deemed reformed in such jurisdiction to the maximum time, geographic, service, or other limitations permitted by applicable law.
The Employee agrees to disclose the existence and terms of this Section 5 to any employer that the Employee may work for during the Restricted Period. If the Employee breaches this Section 5 in any respect, the restrictions contained in
herein will be extended for a period equal to the period that the Employee was in breach. 
 SECTION 6 Miscellaneous.

 6.1. Section 409A. This Agreement shall be interpreted to avoid any penalty sanctions under Section 409A of
the Internal Revenue Code of 1986, as amended (the “Code”). If any payment or benefit cannot be provided or made at the time specified herein without incurring sanctions under Section 409A, then such benefit or payment shall be
provided in full at the earliest time thereafter when such sanctions will not be imposed. All payments to be made upon a termination of employment under this Agreement will be made upon a ‘separation from service’ under Section 409A
of the Code. For purposes of Section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment. In no event may the Employee, directly or indirectly, designate the calendar year of payment. To the maximum
extent permitted under Section 409A of the Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the requirements of the short-term deferral exemption under Section 409A of
the Code and the ‘separation pay exception’ under Treas. Reg. §1.409A-1(b)(9)(iii). However, if such severance benefits do not qualify for such exemptions at the time of the Employee’s termination of employment and therefore are
deemed as deferred compensation subject to the requirements of Section 409A of the Code, then if the Employee is a “specified employee” under Section 409A of the Code on the date of the Employee’s termination of employment,
notwithstanding any other provision of this Agreement, payment of severance under this Agreement shall be delayed for a period of six (6) months from the date of the Employee’s termination of employment if required by Section 409A of
the Code. The accumulated postponed amount shall be paid in a lump sum payment within ten (10) days after the end of the six (6) month period. If the Employee dies during the postponement period prior to payment of the postponed amount,
the amounts withheld on account of Section 409A of the Code shall be paid to the Employee’s estate within sixty (60)

  
 7 

 
days after the date of the Employee’s death. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of
Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement shall be for expenses incurred during the Employee’s lifetime (or during a shorter period of time specified in this Agreement),
(ii) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year, (iii) the
reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or
exchange for another benefit. 
 6.2. Term of Agreement. This Agreement shall continue in full force and effect for the
duration of the Employee’s employment with the Company; provided, however, that after the termination of the Employee’s employment, this Agreement shall remain in effect until all of the obligations of the parties hereunder are
satisfied or have expired. 
 6.3. Successors and Assigns. This Agreement shall inure to the benefit of and be binding
upon the Company and the Employee and their respective successors, executors, administrators, heirs and/or permitted assigns; provided, however, that neither the Employee nor the Company may make any assignments of this Agreement or any
interest herein, by operation of law or otherwise, without the prior written consent of the other party, except that, without such consent, the Company may assign this Agreement to any successor to all or substantially all of its assets and business
by means of liquidation, dissolution, merger, consolidation, transfer of assets, or otherwise. 
 6.4. Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania without regard to the application of the principles of conflicts of laws. 

6.5. Enforcement. Any legal proceeding arising out of or relating to this Agreement will be instituted in the United States
District Court for the Eastern District of Pennsylvania, or if that court does not have or will not accept jurisdiction, in any court of general jurisdiction in the Commonwealth of Pennsylvania, and the Employee and the Company hereby consent to the
personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum. 

6.6. Waivers; Separability. The waiver by either party hereto of any right hereunder or any failure to perform or breach by the
other party hereto shall not be deemed a waiver of any other right hereunder or any other failure or breach by the other party hereto, whether of the same or a similar nature or otherwise. No waiver shall be deemed to have occurred unless set forth
in a writing executed by or on behalf of the waiving party. No such written waiver shall be deemed a continuing waiver unless specifically stated therein, and each such waiver shall operate only as to the specific term or condition waived. Whenever
possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any
applicable law or rule in any jurisdiction, such invalidity, 

  
 8 

 
illegality or unenforceability will not affect any other provision or the effectiveness or validity of any provision in any other jurisdiction, and this Agreement will be reformed, construed and
enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. 
 6.7.
Notices. All notices and communications that are required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given when delivered personally or upon mailing by registered or certified mail, postage
prepaid, return receipt requested, as follows: 
 If to the Company, to: 

ViroPharma Incorporated 
 730 Stockton Drive 
 Exton, PA 19341 

Attn: General Counsel 
 Fax: (610) 458-7830 
 If to the Employee, to the address on file with the
Company, 
 or to such other address as may be specified in a notice given by one party to the other party hereunder. 

6.8. Entire Agreement; Amendments. This Agreement and the attached exhibit contain the entire agreement and understanding of the
parties relating to the provision of severance benefits upon termination in connection with a Change of Control, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to that
subject. 
 6.9. Withholding. The Company will withhold from any payments due to the Employee hereunder, all taxes, FICA
or other amounts required to be withheld pursuant to any applicable law. 
 6.10. Headings Descriptive. The headings of
sections and paragraphs of this Agreement are inserted for convenience only and shall not in any way affect the meaning or construction of any provision of this Agreement. 
 6.11. Counterparts and Facsimiles. This Agreement may be executed, including execution by facsimile signature, in one or more counterparts, each of which shall be deemed an original, and all of
which together shall be deemed to be one and the same instrument. 
 6.12. No Duty to Mitigate. The Employee shall not be
required to mitigate damages or the amount of any payments provided for under this Agreement by seeking other employment or otherwise. 
 6.13. Recoupment Policy. The Employee agrees that the Employee will be subject to any compensation clawback or recoupment policies that may be applicable to the Employee as an executive of the
Company, as in effect from time to time and as approved by the Board or a duly authorized committee thereof, whether or not approved before or after the effective date of this Amendment. 

[signature page follows] 

  
 9 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date and year
first above written. 
  

	
	VIROPHARMA INCORPORATED
	
	  

	By: Vincent J. Milano
	Title: President, Chief Executive Officer and Chairman of the Board of Directors
	
	EMPLOYEE
	
	  

	[    ]

  
 10 

 EXHIBIT A 
 RELEASE AND NON-DISPARAGEMENT AGREEMENT 
 THIS RELEASE AND
NON-DISPARAGEMENT AGREEMENT (this “Release”) is made as of the          day of             ,
             by and between                         
(the “Employee”) and VIROPHARMA, INCORPORATED (the “Company”). 
 WHEREAS, the Employee’s
employment as an executive of the Company has terminated; and 
 WHEREAS, pursuant to Section 2 of the Change of Control
Agreement by and between the Company and the Employee dated as of                     
            ,              (the “Change of Control Agreement”), the Company has agreed to pay the
Employee certain amounts and to provide Employee with certain rights and benefits, subject to the execution of this Release. 

NOW THEREFORE, in consideration of these premises and the mutual promises contained herein, and intending to be legally bound hereby, the
parties agree as follows: 
 SECTION 1 Consideration. The Employee acknowledges that: (a) the payments, rights and
benefits set forth in Section 2 of the Change of Control Agreement constitute full settlement of all of Employee’s rights under the Change of Control Agreement, (b) the Employee has no entitlement under any other severance or similar
arrangement maintained by the Company, and (c) except as otherwise provided specifically in this Release, the Company does not and will not have any other liability or obligation to the Employee. The Employee further acknowledges that, in the
absence of Employee’s execution of this Release, the payments and benefits specified in Section 2 of the Change of Control Agreement would not otherwise be due to the Employee. 

SECTION 2 Release and Covenant Not to Sue. The Employee hereby fully and forever releases and discharges the Company and its
parents, affiliates and subsidiaries, including all predecessors and successors, assigns, officers, directors, trustees, employees, agents and attorneys, past and present (the Company and each such person or entity is referred to as a
“Released Person”), from any and all claims, demands, liens, agreements, contracts, covenants, actions, suits, causes of action, obligations, controversies, debts, costs, expenses, damages, judgments, orders and liabilities, of
whatever kind or nature, direct or indirect, in law, equity or otherwise, whether known or unknown, arising through the date of this Release, out of Employee’s employment by the Company or the termination thereof, including, but not limited to,
any claims for relief or causes of action under the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., or any other federal, state or local statute, ordinance or regulation regarding discrimination in employment and any
claims, demands or actions based upon alleged wrongful or retaliatory discharge or breach of contract under any state or federal law. The Employee expressly represents that he has not filed a lawsuit or initiated any other administrative proceeding
against a Released Person, and that he has not assigned any claim against a Released Person. The Employee further promises not to initiate a lawsuit or to bring any other claim against a Release Person arising out of or in any way related to
Employee’s employment by the Company or the termination of that employment. The forgoing will not be deemed to release the Company from (a) claims solely to enforce this Release, (b) claims solely to enforce Section 2 of the
Change of Control Agreement, (c) claims for indemnification under the Company’s By-Laws, under any indemnification agreement between the Company and the Employee or under any similar agreement or (d) claims solely to enforce the terms
of any equity incentive award agreement between the Employee and the Company. This Release will not prevent the Employee from filing a charge with 

 
the Equal Employment Opportunity Commission (or similar state agency) or participating in any investigation conducted by the Equal Employment Opportunity Commission (or similar state agency);
provided, however, that any claims by the Employee for personal relief in connection with such a charge or investigation (such as reinstatement or monetary damages) would be barred. 

SECTION 3 Restrictive Covenants. The Employee acknowledges that restrictive covenants contained in Section 5 of the Change of
Control Agreement will survive the termination of his employment. The Employee affirms that those restrictive covenants are reasonable and necessary to protect the legitimate interests of the Company, that he received adequate consideration in
exchange for agreeing to those restrictions and that he will abide by those restrictions. 
 SECTION 4 Non-Disparagement.
The Company (meaning, solely for this purpose, the Company’s directors and executive officers and other individuals authorized to make official communications on the Company’s behalf) will not disparage the Employee or the Employee’s
performance or otherwise take any action which could reasonably be expected to adversely affect the Employee’s personal or professional reputation. Similarly, the Employee will not disparage the Company or any of its directors, officers, agents
or employees or otherwise take any action which could reasonably be expected to adversely affect the reputation of the Company or the personal or professional reputation of any of the Company’s directors, officers, agents or employees.

 SECTION 5 Cooperation. The Employee further agrees that, subject to reimbursement of Employee’s reasonable
expenses, he will cooperate fully with the Company and its counsel with respect to any matter (including litigation, investigations, or governmental proceedings) which relates to matters with which the Employee was involved during Employee’s
employment with the Company. The Employee shall render such cooperation in a timely manner on reasonable notice from the Company. 
 SECTION 6 Rescission Right. The Employee expressly acknowledges and recites that he (a) has read and understands this Release in its entirety, (b) as entered into this Release knowingly
and voluntarily, without any duress or coercion; (c) has been advised orally and is hereby advised in writing to consult with an attorney with respect to this Release before signing it; (d) was provided twenty-one (21) calendar
days after receipt of the Release to consider its terms before signing it (or such longer period as is required for this Release to be effective under the Age Discrimination in Employment Act or any similar state law); and (e) is provided seven
(7) calendar days from the date of signing to terminate and revoke this Release (or such longer period required by applicable state law), in which case this Release shall be unenforceable, null and void. The Employee may revoke this Release
during those seven (7) days (or such longer period required by applicable state law) by providing written notice of revocation to the Company at the address specified in Section 6.7 of the Change of Control Agreement. 

SECTION 7 Challenge. If the Employee violates or challenges the enforceability of Section 5 of the Change of Control
Agreement or this Release, no further payments, rights or benefits under Section 2 of the Change of Control Agreement will be due to the Employee. 
 SECTION 8 Miscellaneous. 
 8.1. No Admission of Liability. This
Release is not to be construed as an admission of any violation of any federal, state or local statute, ordinance or regulation or of any duty owed by the Company to the Employee. There have been no such violations, and the Company specifically
denies any such violations. 

 8.2. No Reinstatement. The Employee agrees that he will not apply for reinstatement
with the Company or seek in any way to be reinstated, re-employed or hired by the Company in the future. 
 8.3. Successors
and Assigns. This Release shall inure to the benefit of and be binding upon the Company and the Employee and their respective successors, executors, administrators and heirs. The Employee may make any assignment of this Release or any interest
herein, by operation of law or otherwise. The Company may assign this Release to any successor to all or substantially all of its assets and business by means of liquidation, dissolution, merger, consolidation, transfer of assets, or otherwise.

 8.4. Severability. Whenever possible, each provision of this Release will be interpreted in such manner as to be
effective and valid under applicable law. However, if any provision of this Release is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Release
will be reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained. 
 8.5. Entire Agreement; Amendments. Except as otherwise provided herein, this Release contains the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and
merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to the subject matter hereof. This Release may not be changed or modified, except by an Agreement in writing signed by each of
the parties hereto. 
 8.6. Governing Law. This Release shall be governed by, and enforced in accordance with, the laws
of the Commonwealth of Pennsylvania without regard to the application of the principles of conflicts of laws. 
 8.7.
Counterparts and Facsimiles. This Release may be executed, including execution by facsimile signature, in one or more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same
instrument. 
 IN WITNESS WHEREOF, the Company has caused this Release to be executed by its duly authorized officer, and the
Employee has executed this Release, in each case as of the date first above written. 
  

			
	VIROPHARMA, INCORPORATED
	
	  

	By:	 	
	Title:	 	
	
	EMPLOYEENinth Amended and Restated Investor Rights Agreement

 Exhibit 4.5 
 EXECUTION COPY 
 FLUIDIGM CORPORATION 

NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 November 16, 2009 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	 Page
	 
		
	SECTION 1 Restrictions on Transferability; Registration Rights	  	 	1	  
				
		 	1.1	  	    Certain Definitions	  	 	1	  
		 	1.2	  	    Restrictions	  	 	4	  
		 	1.3	  	    Restrictive Legend	  	 	5	  
		 	1.4	  	    Notice of Proposed Transfers	  	 	5	  
		 	1.5	  	    Requested Registration	  	 	6	  
		 	1.6	  	    Company Registration	  	 	7	  
		 	1.7	  	    Registration on Form S-3	  	 	9	  
		 	1.8	  	    Expenses of Registration	  	 	10	  
		 	1.9	  	    Registration Procedures	  	 	10	  
		 	1.10	  	    Indemnification	  	 	12	  
		 	1.11	  	    Information by Holder	  	 	14	  
		 	1.12	  	    Reports Under Securities Exchange Act of 1934	  	 	14	  
		 	1.13	  	    Transfer of Registration Rights	  	 	15	  
		 	1.14	  	    Standoff Agreement	  	 	15	  
		 	1.15	  	    Termination of Rights	  	 	16	  
		 	1.16	  	    Limitations on Subsequent Registration Rights	  	 	16	  
		
	SECTION 2 Affirmative Covenants of the Company	  	 	16	  
				
		 	2.1	  	    Delivery of Financial Statements	  	 	16	  
		 	2.2	  	    Additional Information Rights	  	 	17	  
		 	2.3	  	    Confidentiality	  	 	18	  
		 	2.4	  	    Visitation Rights	  	 	18	  
		 	2.5	  	    Stock Option Vesting	  	 	18	  
		 	2.6	  	    Insurance	  	 	19	  
		 	2.7	  	    Proprietary Information Agreements	  	 	19	  
		 	2.8	  	    Invention Assignments	  	 	19	  
		 	2.9	  	    Key-Man Life Insurance	  	 	19	  
		 	2.10	  	    Compliance with Laws	  	 	19	  
		 	2.11	  	    Termination of Covenants	  	 	19	  
		
	SECTION 3 Right of First Offer For Company Securities	  	 	19	  
				
		 	3.1	  	    Right of First Offer	  	 	19	  
		 	3.2	  	    Sale of Securities by Company	  	 	20	  
		 	3.3	  	    Offer Amount	  	 	20	  
		 	3.4	  	    Financing	  	 	20	  
		 	3.5	  	    Termination of Right of First Offer	  	 	21	  
		
	SECTION 4 Right of First Offer with Respect to Founder Shares	  	 	21	  
				
		 	4.1	  	    Notice of Sales	  	 	21	  
		 	4.2	  	    Purchase Right	  	 	21	  

  
 -i-

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	 Page
	 
				
		 	4.3	  	    Sale of Securities by Founder	  	 	22	  
		 	4.4	  	    Termination and Transfer	  	 	23	  
		 	4.5	  	    Prohibited Transfer	  	 	23	  
		
	SECTION 5 Right of Co-Sale	  	 	23	  
				
		 	5.1	  	    Notice of Sales	  	 	23	  
		 	5.2	  	    Participation Right	  	 	23	  
		 	5.3	  	    Sale of Securities by Founder	  	 	25	  
		 	5.4	  	    Termination and Transfer	  	 	25	  
		 	5.5	  	    Prohibited Transfers	  	 	25	  
		
	SECTION 6 Miscellaneous	  	 	26	  
				
		 	6.1	  	    Governing Law; Jurisdiction	  	 	26	  
		 	6.2	  	    Successors and Assigns	  	 	27	  
		 	6.3	  	    Notices, Etc	  	 	27	  
		 	6.4	  	    Delays or Omissions	  	 	27	  
		 	6.5	  	    Third Parties	  	 	27	  
		 	6.6	  	    Severability	  	 	27	  
		 	6.7	  	    Amendment and Waiver	  	 	28	  
		 	6.8	  	    Rights of Holders	  	 	28	  
		 	6.9	  	    Counterparts	  	 	28	  
		 	6.10	  	    Titles and Subtitles	  	 	28	  
		 	6.11	  	    Amendment and Restatement of Prior Agreement	  	 	28	  
		 	6.12	  	    Waiver of Right of First Offer	  	 	29	  
		 	6.13	  	    Aggregation of Stock	  	 	29	  
		 	6.14	  	    Jury Trial	  	 	29	  

  
 -ii-

 NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

THIS NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of
November 16, 2009 by and among Fluidigm Corporation, a Delaware corporation (the “Company”), the persons set forth on Exhibit A hereto (the “New Investors”), the persons set forth on the Schedule of
Founders attached hereto as Exhibit B (the “Founders”), and the persons set forth on Exhibit C hereto (the “Prior Investors”). The Prior Investors and the New Investors are referred to herein
collectively as the “Investors.” 
 RECITALS 

WHEREAS, the Company and the New Investors have entered into a Series E Preferred Stock Purchase Agreement of even date herewith, as
amended from time to time (such agreement, as amended from time to time, the “2009 Purchase Agreement”), pursuant to which the Company shall sell, and the New Investors shall acquire, shares of the Company’s Series E Preferred
Stock; 
 WHEREAS, the Company has granted certain registration rights and other rights to the Founders and the Prior Investors
pursuant to that certain Eighth Amended and Restated Investor Rights Agreement dated June 13, 2006, as amended December 22, 2006, as further amended October 10, 2007, and as further amended September 15, 2008 (the “Prior
Agreement”); and 
 WHEREAS, as an inducement to the New Investors to purchase shares of the Company’s Series E
Preferred Stock pursuant to the 2009 Purchase Agreement, the Company, the Prior Investors and the Founders desire to amend and restate the Prior Agreement to allow the New Investors to become a party to this Agreement. 

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the parties agree as follows: 

SECTION 1  

Restrictions on Transferability; Registration Rights 
 1.1    Certain Definitions.  As used in this Agreement, the following terms shall have the following meanings: 

“Affiliate” shall have the meaning set forth in Rule 405 of the Securities Act; provided that the
definition of “Affiliate” shall also include (i) any general partner, officer or director of such person, (ii) any private equity or venture capital fund now or hereafter existing (a “Fund”) for which such person
or an Affiliate of such person is a general partner or management company, and (iii) if such person is a Fund, any other Fund that is directly or indirectly controlled by or under common control with one or more general partners of such person,
or that shares the same management company with such person or an Affiliated management company. 

“Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering
the Securities Act. 

  
 1 

 “Eligible Securities” shall mean (i) the Series A
Preferred Stock issued pursuant to the Series A Preferred Stock Purchase Agreement dated December 1, 1999; (ii) the Series B Preferred Stock issued pursuant to the Series B Preferred Stock Purchase Agreement dated July 5,
2000; (iii) the Series C Preferred Stock issued pursuant to the Series C Preferred Stock Purchase Agreement dated October 23, 2001; (iv) the Series C Preferred Stock issued pursuant to the Series C Preferred Stock
Purchase Agreement dated November 1, 2002; (v) the Series C Preferred Stock issued pursuant to the Series C Preferred Stock and Warrant Purchase Agreement dated September 22, 2003; (vi) the Series D Preferred Stock issued
pursuant to the Series D Preferred Stock Purchase Agreement dated December 18, 2003; (vii) the Series D Preferred Stock issued pursuant to the Series D Preferred Stock Purchase Agreement dated August 16, 2005; (viii) the
Series D Preferred Stock issued upon conversion of convertible promissory note(s) issued pursuant to the Convertible Promissory Note Purchase Agreement (the “CNPA”) dated December 18, 2003, as amended by Amendment No. 1 to
Convertible Note Purchase Agreement dated December 17, 2004, between the Company and Biomedical Sciences Investment Fund Pte Ltd (the “BMSIF”); (ix) the Series D Preferred Stock issued upon conversion of convertible
promissory note(s) issued in connection with the Convertible Note Agreement (the “CNA”) dated December 18, 2003, between the Company and Invus, L.P. (the “Invus”); (x) the Series E Preferred Stock issued
pursuant to the Series E Preferred Stock Purchase Agreement dated June 13, 2006, as amended (the “Prior Purchase Agreement”); (xi); the Series E Preferred Stock issued pursuant to the 2009 Purchase Agreement;
(xii) all Securities acquired by any Investor pursuant to the rights of first offer described in Sections 3 or 4 of this Agreement; and (xiii) any Securities issued with respect to the foregoing upon any stock split, stock dividend,
recapitalization, or similar event or upon any exercise or conversion, as applicable. 
 “Exchange Act” shall
mean the Securities Exchange Act of 1934, as amended, or any similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Founders Shares” shall mean the shares of Common Stock of the Company issued to the Founders as of the date of this
Agreement or at any time in the future. 
 “Holder” shall mean (i) any Investor and any person to whom
registration rights under this Agreement have been transferred in accordance with Section 1.13 hereof, (ii) for the purposes of Section 1.6 (and other portions of this Section 1, to the extent they relate to rights of
registration under Section 1.6), any Founder or holder of Other Shares and (iii) for the purposes of Sections 1.5, 1.6 and 1.7 (and other portions of this Section 1, to the extent they relate to rights of registration under
Sections 1.5, 1.6 and 1.7), Warrantholders. 
 “Initial Public Offering” shall mean the first sale of
Securities of the Company pursuant to an effective registration statement under the Securities Act. 

“Initiating Holders” shall mean Holders who in the aggregate hold a majority of the Registrable Securities then
held by Holders assuming conversion or exercise, as applicable, of all Eligible Securities. 
 “Lighthouse Preferred
Warrants” shall mean (i) the Preferred Stock Purchase Warrant, dated March 29, 2005, pursuant to which Lighthouse Capital Partners V, L.P. (“Lighthouse”) may purchase shares of the Company’s authorized Series
D Preferred Stock; (ii) the 

  
 2 

 
Preferred Stock Purchase Warrant, dated February 15, 2008, pursuant to which Lighthouse may purchase shares of the Company’s authorized Series E Preferred Stock; and (iii) the
Preferred Stock Purchase Warrant, dated March 25, 2009, pursuant to which Lighthouse may purchase shares of the Company’s authorized Series E Preferred Stock. 
 “Other Shares” shall mean the shares of Common Stock of the Company issued pursuant to the Common Stock Purchase Agreements dated July 17, 2001 and February 2005 by and between the
Company and President and Fellows of Harvard College. 
 “Permitted Transferee” shall mean (i) any
general partner or retired general partner of any Holder which is a partnership; (ii) any family member of a Holder or trust for the benefit of any individual Holder; (iii) any Investor; (iv) an Affiliate of an Investor; or
(v) any transferee who acquires at least 40,000 shares of Eligible Securities. 
 The terms “register,”
“registered” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such
registration statement. 
 “Registration Expenses” shall mean all expenses incurred by the Company in
complying with Sections 1.5, 1.6 and 1.7 hereof, including, without limitation, all registration, qualification, stock exchange and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company and accountants
and other persons retained by or for the Company (including the fees of one counsel for the Holders, not to exceed $25,000), blue sky fees and expenses, accounting fees and the expense of any special audits incident to or required by any such
registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company). 
 “Registrable Securities” means (i) any shares of Common Stock which are Eligible Securities, (ii) any shares of Common Stock issuable upon the exercise or conversion, as
applicable, of Eligible Securities, (iii) for the purposes of Section 1.6 (and other portions of this Section 1, to the extent they relate to rights of registration under Section 1.6) any shares of Common Stock which are Founder
Shares or Other Shares, and (iv) for the purposes of Sections 1.5, 1.6 and 1.7 (and other portions of this Section 1, to the extent they relate to rights of registration under Sections 1.5, 1.6 and 1.7) any shares of Common Stock
which are Warrant Shares; provided, however, that shares of Common Stock shall be treated as Registrable Securities only if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a public
distribution or a public securities transaction, (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions and restrictive
legends with respect thereto are removed upon the consummation of such sale or (C) sold in a transaction in which the rights granted under this Section 1 are not assigned in accordance with this Agreement. 

“Restricted Securities” shall mean the securities of the Company required to bear the legends set forth in
Section 1.3 hereof. 
 “Securities” shall mean shares of, or securities convertible into or exercisable
for any shares of, any class of capital stock of the Company. 

  
 3 

 “Securities Act” shall mean the Securities Act of 1933, as amended, or any
similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Selling Expenses” shall mean all underwriting discounts and selling commissions and applicable to the securities registered by the Holders and any fees and disbursements of counsel for
the Holders not included in the definition of Registration Expenses. 
 “Voting Agreement” shall mean the
Second Amended and Restated Voting Agreement dated August 16, 2005 among the Company and certain stockholders of the Company. 
 “Warrant Shares” shall mean the shares of Common Stock of the Company issued or issuable upon conversion of the (i) Series C Preferred Stock issued or issuable upon exercise or
conversion of (A) the warrant to purchase up to 17,500 shares of Series C Preferred Stock issued to TBCC Funding Trust II (“TBCC”) pursuant to the Master Loan and Security Agreement dated March 27, 2002 by and between the
Company and Transamerica Technology Finance Corporation; (B) the warrant to purchase up to 31,008 shares of Series C Preferred Stock issued to General Electric Capital Corporation (“GE Capital”) in connection with the Master
Security Agreement dated as of November 8, 2002, as amended (the “Master Security Agreement”) by and between the Company and GE Capital; (C) the warrants to purchase an aggregate of up to 90,000 shares of Series C
Preferred Stock issued to Glaxo Group Limited (“GGL”) in connection with the Development Collaboration and License Agreement dated September 22, 2003 (the “License Agreement”); and (D) the warrants to
purchase an aggregate of up to 110,000 shares of Series C Preferred Stock issued to SmithKline Beecham Corporation (“SBC”) in connection with the License Agreement; (ii) the Series D Preferred Stock issued or issuable upon
exercise or conversion of (A) the warrant to purchase up to 37,500 shares of Series D Preferred Stock dated March 18, 2004 and issued to GE Capital in connection with extensions of credit to the Company; (B) the warrant to purchase up
to 380,556 shares of Series D Preferred Stock dated June 30, 2004 and issued to In-Q-Tel, Inc. (“In-Q-Tel”); (C) the Lighthouse Preferred Warrants; and (D) the warrant to purchase up to 126,851 shares of Series D
Preferred Stock dated June 30, 2004 and issued to In-Q-Tel Employee Fund, LLC (“Employee Fund”); and (iii) the Series E Preferred Stock issued or issuable upon exercise or conversion of (A) the Lighthouse
Preferred Warrants and (B) the warrants to purchase shares of Preferred Stock of the Company issued to certain Investors under the Note and Warrant Purchase Agreement dated as of August 25, 2009. GGL, SBC, TBCC, GE Capital, In-Q-Tel,
Employee Fund, and Lighthouse are collectively referred to herein as “Warrantholders.” 
 “Worthington
Shares” shall mean the Founder Shares issued to Gajus Worthington or his Affiliates. 

1.2    Restrictions.  No Restricted Securities shall be sold, assigned, transferred or pledged
except upon the conditions specified in this Agreement. Each Holder will cause any proposed purchaser, assignee, transferee or pledgee of its Restricted Securities to agree in writing to take and hold such securities subject to the provisions and
upon the conditions specified in this Agreement, including, without limitation, Section 1.14, except where such Restricted Securities would cease to be Restricted Securities in connection with such proposed purchase, assignment, transfer or
pledge. 

  
 4 

 1.3    Restrictive Legend.  Each certificate
representing Registrable Securities shall (unless otherwise permitted by the provisions of Section 1.4 below) be stamped or otherwise imprinted with a legend in the following form (in addition to any legend required under applicable state
securities laws): 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). SUCH SHARES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL (WHICH MAY BE
COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT.” 

“THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY
AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.” 
 “THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO A MARKET STAND-OFF AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.” 
 Each Holder consents to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer
established in this Section 1. 
 1.4    Notice of Proposed Transfers.  Each Holder
of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the restrictions on transfer contained in Sections 1.2, 1.3, 1.4 and 1.14 of this Agreement. Solely for purposes of the foregoing
sentence and for the sake of clarification, the term “Holder” shall also include and the term “Restricted Securities” shall also apply to any Founder, holder of Other Shares or Warrantholders. Prior to any proposed sale,
assignment, transfer or pledge of any Restricted Securities (other than any transfer not involving a change in beneficial ownership), unless there is in effect a registration statement under the Securities Act covering the proposed transfer, the
Holder thereof shall give written notice to the Company of such Holder’s intention to effect such transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or
pledge in sufficient detail, and shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall be, reasonably satisfactory to the Company, addressed to the Company,
to the effect that the proposed transfer of the Restricted Securities may be effected without registration under the Securities Act and applicable state securities laws, or (ii) a “no action” letter from the Commission to the effect
that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, or (iii) any 

  
 5 

 
other evidence reasonably satisfactory to counsel to the Company, whereupon the Holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with
the terms of the notice delivered by the Holder to the Company; provided, however, that no such legal opinion, “no action” letter or other evidence shall be required with respect to a transfer to an Affiliate. Each
certificate evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 1.3 above, except that such
certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and reasonably acceptable to the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act or this
Agreement. 
 1.5    Requested Registration. 

(a)      Request for Registration.  In case the Company shall receive from Initiating
Holders a written request that the Company effect any registration with respect to a public offering of at least 50% of the Registrable Securities, the reasonably anticipated aggregate price to the public of which, net of underwriting discounts and
commissions, would exceed $20,000,000, the Company will: 
 (i)    promptly give written notice of the
proposed registration to all other Holders; and 
 (ii)   use its best efforts to effect as soon as practicable
such registration (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable
regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are
specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within 15 days after receipt of the written
notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any such registration pursuant to this Section 1.5: 

(1)    Prior to six months following the closing of the Company’s Initial Public Offering; 

(2)    During the period starting with the date 60 days prior to the Company’s estimated date of filing of, and
ending on the date three months immediately following the effective date of, any registration statement (other than a registration of Securities in a Rule 145 transaction or with respect to an employee benefit plan) pertaining to Securities of the
Company (subject to Section 1.6(a) hereof), provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to be filed and become effective and that the Company provides the Initiating
Holders written notice of its intent to file such registration statement within 30 days of receiving the request for registration from the Initiating Holders and provided further, however, that the Company may not utilize this right more than
once in any 12-month period. 

  
 6 

 (3)    After the Company has effected two registrations pursuant to
this Section 1.5; or 
 (4)    If the Company shall furnish to such Holders a certificate, signed by
the President of the Company, stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future, in which case the
Company’s obligation to use its best efforts to register under this Section 1.5 shall be deferred for a period not to exceed 90 days from the date of receipt of written request from the Initiating Holders; provided, however, that the
Company may not utilize this right more than once in any 12-month period. 

(b)    Underwriting.  If the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as part of their request made under Section 1.5(a), and the Company shall so advise the Holders as part of the notice given pursuant to
Section 1.5(a)(i). The right of any Holder to registration pursuant to Section 1.5 shall be conditioned upon such Holder’s participation in the underwriting arrangements required by this Section 1.5 and the inclusion of such
Holder’s Registrable Securities in the underwriting, to the extent requested and provided herein. 
 The Company shall
(together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company and a majority of the
Holders. Notwithstanding any other provision of this Section 1.5, if the managing underwriter advises the Company in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so
advise all Holders of Registrable Securities who indicated their intent to participate in the registration in a timely manner, and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be
allocated among such Holders in proportion, as nearly as practicable, to the respective number of Registrable Securities held by such Holders at the time of filing the registration statement, provided, however, that the number of
shares of Registrable Securities to be included in such underwriting shall not be reduced unless all Worthington Shares, all Other Shares and all other Securities that are not Registrable Securities (other than Securities to be sold for the account
of the Company) are first entirely excluded from the underwriting. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 If any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the managing underwriter and the
Initiating Holders. The Registrable Securities so withdrawn shall also be withdrawn from registration. 

1.6    Company Registration. 
 (a)    Notice of Registration.  If at any time or from time to time, the Company shall determine to register any Common Stock, either for its own account or the
account of a security holder or holders other than (i) a registration relating to employee benefit plans, (ii) a 

  
 7 

 
registration relating to the offer and sale of debt securities, (iii) a registration relating to a Commission Rule 145 transaction, or (iv) a registration pursuant to
Sections 1.5 or 1.7 hereof, the Company will: 
 (i)    promptly give to each Holder written notice
thereof; and 
 (ii)   include in such registration (and any related qualification under blue sky laws or other
compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests made within 15 days after receipt of such written notice from the Company by any Holder. 

(b)      Underwriting.  If the registration of which the Company gives notice is for a
registered public offering involving an underwriting, the Company shall so advise the Holders in a written notice given pursuant to this Section 1.6. In such event, the right of any Holder to registration pursuant to this Section 1.6 shall
be conditioned upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. 
 All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into an
underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 1.6, if the managing underwriter advises the Company in writing that
marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and
underwriting shall be allocated among all Holders thereof in proportion, as nearly as practicable, to the respective number of Registrable Securities held by such Holders at the time of filing the registration statement; provided,
however, that, no Registrable Securities shall be excluded until all Worthington Shares, all Other Shares and all other Securities that are not Registrable Securities (other than Securities to be sold for the account of the Company) are first
excluded, and provided further, that, except in the case of the Company’s Initial Public Offering (where Registrable Securities may be excluded entirely), the number of Registrable Securities included in such underwriting shall not be
reduced below 25% of the total number of shares in the underwriting. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. The Company may include shares of Common Stock held by stockholders other
than Holders in a registration statement pursuant to this Section 1.6 to the extent that the amount of Registrable Securities otherwise includible in such registration statement would not thereby be diminished. 

If any Holder or other holder disapproves of the terms of any such underwriting, he or she may elect to withdraw therefrom by written
notice to the Company and the managing underwriter. The Registrable Securities so withdrawn shall also be withdrawn from such registration and, in the case of the Company’s Initial Public Offering, shall be subject to Section 1.14.

  
 8 

 (c)    Right to Terminate Registration.  The Company
shall have the right to terminate or withdraw any registration initiated by it under this Section 1.6 prior to the effectiveness of such registration, whether or not any Holder has elected to include securities in such registration. 

1.7    Registration on Form S-3. 

(a)      If any Holder or Holders request that the Company file a registration statement on Form S-3
(or any successor form to Form S-3) for a public offering of Registrable Securities, the reasonably anticipated aggregate price to the public of which, net of underwriting discounts and commissions, would exceed $2,000,000, and the Company is
then entitled to use Form S-3 under applicable Commission rules to register the Registrable Securities for such an offering, the Company will: 
 (i)    promptly give written notice of the proposed registration to all other Holders; and 
 (ii)   use its best efforts to effect as soon as practicable such registration (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate
qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request
as are specified in a written request received by the Company within 15 days after receipt of the written notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any such
registration pursuant to this Section 1.7: 
 (1)    if the Company, within ten (10) days of the
receipt of the request for registration pursuant to this Section 1.7, gives notice of its bona fide intention to effect the filing of a registration statement with the Commission within ninety (90) days of receipt of such request
(other than with respect to a registration statement relating to a Rule 145 transaction or an employee benefit plan or any other registration which is not appropriate for the registration of Registrable Securities); 

(2)    during the period starting with the date sixty (60) days prior to the Company’s estimated date of
filing of, and ending on the date three months immediately following, the effective date of any registration statement pertaining to Securities of the Company (other than with respect to a registration statement relating to an employee benefit
plan), provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to be filed and become effective; or 
 (3)    if the Company shall furnish to such Holder or Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors it
would be seriously detrimental to the Company or its stockholders for registration statements to be filed in the near future, then the Company’s obligation to use its best efforts to file a registration statement shall be deferred for a period
not to exceed 90 days from the receipt of the request to file such registration by such Holder or Holders; provided further, however, 

  
 9 

 
that the Company may not utilize the rights provided for in subsections (1) and (2) above and this subsection (3) more than once in total in any twelve month period. For the
avoidance of doubt, if the Company utilizes any of the rights provided for in subsections (1), (2) and (3), it shall not have the right to utilize the same right again; nor shall it have the right to utilize any of the other rights provided in
subsections (1), (2) and (3) for twelve months. 
 (b)    Underwriting.  If the
Holders requesting registration intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as part of their request made under Section 1.7(a), and the Company shall so
advise the Holders as part of the notice given pursuant to Section 1.7(a)(i). The substantive provisions of Section 1.5(b) shall otherwise apply to such registration. 

1.8    Expenses of Registration.  All Registration Expenses incurred in connection with any
registration pursuant to Sections 1.5, 1.6 and 1.7 shall be borne by the Company. If a registration proceeding is begun upon the request of Holders pursuant to Section 1.5 or 1.7, but such request is subsequently withdrawn at the request
of the Holders, then the Holders of Registrable Securities to have been registered may either: (i) bear all Registration Expenses of such proceeding, pro rata on the basis of the number of shares to have been registered, in which case the
Company shall be deemed not to have effected a registration pursuant to Section 1.5(a) or 1.7(a) of this Agreement as applicable; provided, however, that the Company, and not the Holders, shall be required to pay for the
Registration Expenses if the Holders learn of a materially adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request promptly following discovery
of such material adverse change; or (ii) if the registration is being effected pursuant to Section 1.5, require the Company to bear all Registration Expenses of such proceeding, in which case the Company shall be deemed to have
effected a registration pursuant to Section 1.5(a). Unless otherwise stated, all other Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of the registered securities included in such
registration pro rata on the basis of the number of shares so registered, provided that to the extent a Holder elects to retain its own counsel (an “Additional Counsel”) separate from the counsel for all the Holders
permitted pursuant to the definition of “Registration Expenses” under Section 1.1, then such Holder shall exclusively bear the costs of such Additional Counsel. 

1.9    Registration Procedures.  In the case of each registration, qualification or compliance
effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification and compliance and as to the completion thereof. At its expense the Company will,
as expeditiously as reasonably possible: 
 (a)    Prepare and file with the Commission a registration
statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for a period of up to one hundred twenty (120) days or until the distribution described in the registration statement has been completed; provided, however, that such 120-day period shall be
extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company. 

  
 10 

 (b)    Prepare and file with the Commission, in consultation with the
Holders, such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of
all securities covered by such registration statement. 
 (c)    Furnish to the Holders participating in
such registration and to the underwriters of the securities being registered such reasonable number of copies of the registration statement, preliminary prospectus, final prospectus and such other documents as such underwriters may reasonably
request in order to facilitate the public offering of such securities. 
 (d)    Use its best efforts to
register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may
be required by the Securities Act. 
 (e)    In the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement. 
 (f)    Notify each Holder of Registrable Securities covered by such registration statement at
any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and at the request of any such Holder,
prepare and furnish to such Holder a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing. 

(g)    Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange,
or quoted in a U.S. automated inter-dealer quotation system, as the case may be, on which similar securities issued by the Company are then listed or quoted. 
 (h)    Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not
later than the effective date of such registration. 
 (i)    In the event of any underwritten public
offering, cooperate with the selling Holders, the underwriters participating in the offering and their counsel in any due diligence investigation reasonably requested by the selling Holders or the underwriters in connection therewith, and
participate, to the extent reasonably requested by the managing underwriter for the 

  
 11 

 
offering or the selling Holder, in efforts to sell the Registrable Securities under the offering (including, without limitation, participating in “roadshow” meetings with prospective
investors) that would be customary for underwritten primary offerings of a comparable amount of equity securities by the Company. 
 1.10  Indemnification. 
 (a)    The Company
will indemnify and defend each Holder, each of its officers and directors and partners, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or
compliance is being effected pursuant to this Section 1, and each underwriter, if any, and each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages or
liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained
in any registration statement, prospectus, preliminary prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration, qualification or compliance, or based on any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation or any alleged violation by the Company of
the Securities Act or the Exchange Act or any state securities law, or any rule or regulation promulgated thereunder, applicable to the Company in connection with any such registration, qualification or compliance, and the Company will reimburse
each such Holder, each of its officers and directors, and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with
investigating, preparing or defending any such claim, loss, damage, liability or action, as such expenses are incurred, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or
expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder,
controlling person or underwriter and stated to be specifically for use therein. 
 (b)    Each Holder
will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter, if any, of
the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder, each of its officers and
directors and each person controlling such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or
alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the Company, such Holders, such directors, officers, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with
investigating or defending any such claim, loss, damage, liability or action, as such expenses are incurred, in each 

  
 12 

 
case to the extent, but only if and to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus,
offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically for use therein; provided, however,
that the liability of any Holder shall be limited to the net proceeds received by such Holder from the sale of Securities pursuant to such registration. 
 (c)    Each party entitled to indemnification under this Section 1.10 (the “Indemnified Party”) shall give notice to the party required to provide indemnification
(the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the
Indemnified Party may participate in such defense at such party’s expense; provided, however, that an Indemnified Party (together with all other Indemnified Parties which may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or
potential differing interests between such Indemnified Party and any other party represented by such counsel in such proceeding. The failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Section 1 unless, and only to the extent that, the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim or litigation. 
 (d)    If the
indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to therein, then the Indemnifying
Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect
the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant
equitable considerations (except to the extent that contribution is not permitted under Section 11(f) of the Securities Act); provided, however, that, no Holder will be required to pay any amount under this subsection 1.10(d)
in excess of the net proceeds from the sale of all Registrable Securities offered and sold by such Holder pursuant to such registration statement. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 

  
 13 

   (e)    Notwithstanding the foregoing, to the extent that
the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement
shall control with respect to the rights and obligations of each of the parties to such underwriting agreement. 

  (f)    The obligations of the Company and Holders under this Section 1.10 shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 

1.11     Information by Holder.  The Holder or Holders of Registrable Securities included in any
registration shall furnish to the Company such information regarding such Holder or Holders, the Securities held by them and the distribution proposed by such Holder or Holders as the Company may reasonably request in writing and as shall be
required in connection with any registration referred to in this Section 1. 
 1.12     Reports
Under Securities Exchange Act of 1934.  With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit a
Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to use its best efforts to: 
   (a)    make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act, at all times after the effective
date that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act; 

  (b)    file with the Commission in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); 
   (c)    register its Common Stock under Section 12 of the Exchange Act at such time as it is required to do so pursuant to the Exchange Act; and 

  (d)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon
request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company),
the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies),
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information in the possession of or reasonably obtainable by the Company as may be
reasonably requested in availing any Holder of any rule or regulation of the Commission which permits the selling of any such securities without registration or pursuant to such form. 

  
 14 

 1.13     Transfer of Registration Rights.  The rights
to cause the Company to register Registrable Securities granted to the Investors under Sections 1.5, 1.6 and 1.7 may be assigned to a transferee or assignee in connection with any transfer or assignment of Eligible Securities by an Investor;
provided that (a) such transfer may otherwise be effected in accordance with applicable securities laws, (b) notice of such assignment is given to the Company, (c) such transferee is a Permitted Transferee and (d) such transferee
or assignee agrees to be bound by and subject to the terms and conditions of this Agreement. 
 1.14
    Standoff Agreement. 
   (a)    Each Holder agrees in connection
with the first sale of the Company’s Common Stock in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, upon notice by the Company or the underwriters managing such public
offering, not to sell, make any short sale of, loan, pledge (or otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or indirectly dispose of any Securities (other than those included in the registration)
without the prior written consent of the Company and such managing underwriters for such period of time as the Board of Directors establishes pursuant to its good faith negotiations with such managing underwriters; provided, however that:

 (i)    such agreement shall not exceed one hundred and eighty (180) days (or such greater period,
not to exceed 17 days, as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including,
but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto); 
 (ii)    such agreement shall not apply to transfers to an Affiliate, provided that such Affiliate agrees to be bound by the terms of such agreement, to the same extent as if such
transferee were the original party thereunder; 
 (iii)    such agreement shall not apply to securities of
the Company purchased by AllianceBernstein Venture Fund I, L.P., SmallCap World Fund, Inc., Cross Creek Capital, L.P., Cross Creek Capital Employees’ Fund, L.P. or Wasatch Small Cap Growth or their respective Affiliates in the Initial Public
Offering or in the public market for the Company’s securities following the Initial Public Offering; 

(iv)    a Holder shall not be subject to such agreement unless (A) all executive officers and directors of the
Company, (B), all stockholders of the Company holding more than 1% of the Company’s outstanding capital stock; and (C) all other Holders and holders of other registration rights, are subject to or obligated to enter into similar
agreements; and 
 (v)    if and when any person identified in clause (iv) is released, in whole or in
part, from such agreement (whether or not such release is contemplated at the time of the offering) or if any such agreement is terminated, the Holder shall be concurrently released on a pro rata basis based on the number of shares held by such
person and the Holder. 

  
 15 

   (b)  Each Holder agrees that prior to the Initial Public Offering it
will not transfer securities of the Company unless each transferee agrees in writing to be bound by all of the provisions of this Section 1.14; provided that this Section 1.14(b) shall not apply to transfers pursuant to a registration
statement. 
   (c)  Each Holder hereby consents to the placement of stop transfer orders with the
Company’s transfer agent in order to enforce the foregoing provision and agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of this Section 1.14. 

1.15     Termination of Rights.  No Holder shall be entitled to exercise any right provided for in
this Section 1 after the earlier of (i) five (5) years following the consummation of the Initial Public Offering, and (ii) that date following the Initial Public Offering upon which each Holder holds less than 1% of the then
issued and outstanding shares of capital stock of the Company and all such shares may be sold under Section 5 of the Securities Act whether pursuant to Rule 144 or another applicable exemption during any 90 day period. All other provisions
hereof relating to registration rights shall continue to be effective despite any termination of such registration rights pursuant to this section. 
 1.16     Limitations on Subsequent Registration Rights.  From and after the date of this Agreement, the Company shall not enter into any agreement granting any holder
or prospective holder of any securities of the Company registration rights with respect to such securities unless (i) such new registration rights, are subordinate to the registration rights granted Holders hereunder and include similar market
stand-off obligations or (ii) such new registration rights are approved by the Holders of 50% of the Registrable Securities then held by Holders (assuming exercise or conversion of all outstanding Eligible Securities); provided,
however, that Warrantholders may enter into this Agreement by executing and delivering a counterpart signature page to this Agreement. 
 SECTION 2 
 Affirmative Covenants of the Company 

The Company hereby covenants and agrees as follows: 
 2.1     Delivery of Financial Statements.  The Company will furnish to each Investor who holds at least 40,000 shares of Eligible Securities (as adjusted for stock
splits and combinations): 
 (a)    as soon as reasonably practicable, an income statement for such fiscal
year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a cash flow statement for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally
accepted accounting principles (“GAAP”), and audited and certified by independent public accountants of nationally recognized standing selected by the Company; and 

(b)    as soon as practicable, but in any event within forty-five (45) days after the end of each of the first
three (3) quarters of each fiscal year of the Company, an unaudited 

  
 16 

 
income statement, cash flow statement for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter. 

2.2     Additional Information Rights. 

(a)    Budget and Operating Plan.  The Company will furnish to each Investor who holds at least
750,000 shares of Eligible Securities (as adjusted for stock splits and combinations) as soon as practicable upon approval or adoption by the Company’s Board of Directors, and in any event within 15 days prior to the start of a fiscal year, the
Company’s budget and operating plan for such fiscal year. 
 (b)    Other
Information.  The Company will furnish to each Investor who holds at least 750,000 shares of Eligible Securities (as adjusted for stock splits and combinations) such other information relating to the financial condition, business,
prospects or corporate affairs of the Company as such Investor may from time to time request; provided, however, that the Company shall not be obligated under this subsection (b) or any other subsection of Section 2.2 to
provide information which it deems in good faith to be a trade secret or similar confidential information. 

(c)    Inspection.  The Company shall permit each Investor who holds at least 750,000 shares of
Eligible Securities (as adjusted for stock splits and combinations), at such Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances
and accounts with its officers, all at such reasonable times and during normal working hours as may be requested by such Investor; provided, however, that the Company shall not be obligated under this subsection (c) or any other
subsection of Section 2.2 to provide access to information which it deems in good faith to be a trade secret or similar confidential information. 
 (d)    Monthly Financial Statements.  The Company will furnish to each Investor who holds at least 750,000 shares of Eligible Securities (as adjusted for stock splits
and combinations), upon the request of such Investors, within thirty (30) days of the end of each month, an unaudited income statement and cash flow statement and unaudited balance sheet for and as of the end of such month, in reasonable
detail. 

  
 17 

 2.3    Confidentiality.  Each Investor agrees to use
commercially reasonable efforts to maintain the confidentiality of information obtained pursuant to this Section 2, provided that such obligation shall not apply to (i) information previously in possession or independently developed by
Investor, (ii) information publicly available other than as a result of breach of this provision (iii) information required to be disclosed by statute, regulation or court or administrative order. Notwithstanding anything to the contrary
set forth in this Agreement, in any other agreement to which the Company and an Investor are party or in any statute (to the extent permitted by applicable law), the Company may withhold any information or material from an Investor if the
Company’s management or the Board of Directors reasonably determine that (a) the information or material is commercially or competitively sensitive for the Company, (b) such Investor is a competitor or potential competitor of the
Company, and (c) disclosure of such information or material to such Investor would be harmful or potentially harmful to the interests of the Company. 
 2.4    Visitation Rights.  One representative chosen collectively by LB I Group Inc., Lehman Brothers P.A. LLC, Lehman Brothers Partnership Account 2000/2001, L.P. and
Lehman Brothers Offshore Partnership Account 2000/2001, L.P. (collectively, “Lehman”), one representative chosen collectively by EuclidSR Partners, L.P. and EuclidSR Biotechnology Partners, L.P. (collectively,
“EuclidSR”), one representative chosen by Piper Jaffray Healthcare Fund III, L.P. (“Piper Jaffray”), one representative chosen by GE Capital Equity Investments, Inc. (“GE Capital”), one
representative chosen collectively by Interwest Investors VII, L. P. and Interwest Partners VII, L.P. (collectively, “Interwest”), one representative chosen by AllianceBernstein Venture Fund I, L.P. (“Alliance”),
one representative chosen collectively by Cross Creek Capital, L.P., Cross Creek Capital Employees’ Fund, L.P. and Wasatch Small Cap Growth (collectively, “Wasatch”), one representative chosen by BMSIF, and one
representative chosen collectively by the holders of a majority of the Shares purchased under that certain Amendment No. 2 to the Series E Preferred Stock Purchase Agreement effective as of October 10, 2007 (collectively, the
“October 2007 Representative”) shall have the right to attend all meetings of the Board of Directors, including meetings of any committee of the Board and including the right to participate in any telephonic board meetings, so long
as such Investor or the October 2007 Representative holds at least 750,000 shares of Eligible Securities (as adjusted for stock splits and combinations and the like). Said representative(s) shall be provided with notice of the meetings in the same
manner at the same time as the members of the Board of Directors and shall be provided with any materials distributed to the Board of Directors in connection with board meetings. The foregoing visitation rights may be limited by the Board of
Directors if (i), upon the advice of counsel, the Board of Directors determines that exclusion is required by third party confidentiality agreements, (ii) the Board is discussing engaging Investor or an affiliate of Investor as a financial
advisor or underwriter; or (iii) the Board is discussing a material transaction with an entity in which Investor or a private equity fund affiliated with Investor is a 5% or greater stockholder, or (iv) the Board determines in good faith
upon advice of counsel that limitations are required to maintain attorney-client privilege. 

2.5    Stock Option Vesting.  Unless otherwise decided by the Board of Directors, all option grants
to employees shall vest over a four-year period with 25% of the shares subject to each option vesting a year after commencement of employment and the remainder of the shares vesting in equal amounts on a monthly basis thereafter. 

  
 18 

 2.6    Insurance.  The Company shall, subject to the
approval of the Board of Directors, maintain such fire, casualty and general liability insurance with coverages and in amounts as shall be determined by the Board of Directors. The Company agrees to maintain in full force and effect directors and
officers liability insurance with coverage in the aggregate amount of amount of $2 million covering all of its directors. The Company will maintain coverage for the Series C Directors (as defined in the Voting Agreement) and the Series D
Directors (as defined in the Voting Agreement) under such directors and officers liability insurance at all times commencing upon the Closing (as defined in the Series D Preferred Stock Purchase Agreement dated August 16, 2005).

 2.7    Proprietary Information Agreements.  Unless otherwise determined by the Board of
Directors, all future employees and consultants of the Company shall be required to execute and deliver a proprietary information and invention assignment agreement. 
 2.8    Invention Assignments.  The Company agrees to use commercially reasonable efforts to obtain from each of the individual contributing inventors for each
invention that forms any part of any patent or patent application owned by or licensed to the Company, executed invention assignments in favor of the Company or the appropriate third party licensor, as the case may be. 

2.9    Key-Man Life Insurance.  The Company shall obtain and maintain key-man life insurance in
such amount as is determined by the Company’s Board of Directors, on Gajus Worthington. Such policy shall name the Company as loss payee and shall not be cancelable by the Company without prior unanimous approval of the Board of Directors.

 2.10    Compliance with Laws.  The Company shall use its best efforts to comply with
the requirements of all applicable laws, rules, regulations and orders of any governmental authority, where noncompliance would have a material adverse effect on the Company’s business and financial condition. 

2.11    Termination of Covenants.  The covenants set forth in Section 2 shall terminate on,
and be of no further force or effect after, the closing of the Company’s Initial Public Offering. The rights granted pursuant to this Section 2 are not transferable other than to Affiliates of Holders. 

SECTION 3 

Right of First Offer For Company Securities 
 3.1    Right of First Offer.  Subject to the terms and conditions specified in this Section 3, the Company hereby grants to each Investor a right of first offer
with respect to future sales by the Company of its Securities. An Investor shall be entitled to apportion the right of first offer hereby granted among itself and its partners and Affiliates in such proportions as it deems appropriate. 

Each time the Company proposes to offer any Securities in a Financing (as defined below), the Company shall first make an offering of
such Securities to each Investor in accordance with the following provisions: 

  
 19 

 (a)    The Company shall deliver a notice (“Notice”)
to each Investor stating (i) its intention to offer such Securities for sale, (ii) the number of such Securities to be offered (the “Offered Securities”), (iii) the price, if any, for which it proposes to offer such
Securities, (iv) the terms of such offer and (v) the Offer Amount (as defined below). 

(b)    Within fifteen (15) calendar days after receipt of the Notice, each Investor may elect to purchase, at
the price and on the terms specified in the Notice, such Securities in an amount up to the Offer Amount by providing the Company with written notice of its election. 
 (c)    An election by an Investor pursuant to Section 3.1(b) to purchase Offered Securities shall not be considered a binding commitment on the Investor unless and until the
Company receives binding commitments to purchase on the terms and conditions contained in the Notice substantially all of the Offered Securities which the Investors have not elected to purchase. 

Notwithstanding the foregoing, the Company and each of the Investors acknowledge and agree that Lighthouse shall have the opportunity to
invest not less than $250,000 in connection with the first Financing completed after the date of this Agreement that involves the sale and issuance by the Company of shares of the Company’s convertible preferred stock with aggregate gross
proceeds to the Company of at least $3 million. In the event that Lighthouse’s right to purchase Offered Securities as otherwise set forth in this Section 3.1 would not permit such $250,000 investment, then each of the Investors agrees
that its respective right to purchase Offered Securities pursuant to this Section 3.1 may be cut-back (proportionately with all other Investors based on the number of shares of Eligible Securities held by the Investors) in such amounts as may
be necessary to permit the exercise of Lighthouse’s rights as set forth herein. 
 3.2     Sale of
Securities by Company.  Within 60 days of the expiration of the period described in Section 3.1(b), any Offered Securities which the Investors have not elected to purchase may be sold by the Company to any person or persons at a
price not less than, and upon terms no more favorable to the offeree than, those specified in the Notice. If the Company does not complete the sale of all such Offered Securities within said 60-day period, the rights of the Investors with respect to
any such unsold Offered Securities shall be deemed to be revived. 
 3.3     Offer
Amount.  The “Offer Amount” shall equal that percentage of the Offered Securities equal to the number of shares of Eligible Securities held by an Investor which are Registrable Securities divided by the total number of
outstanding shares of Common Stock of the Company. For the purposes of the foregoing calculations, all outstanding options and warrants shall be deemed to be exercised and all Preferred Stock shall be deemed to have been converted into Common Stock
at the prevailing conversion rate. 
 3.4     Financing.  “Financing”
shall mean an offering or series of related offerings of Securities by the Company for purposes of raising working capital in a minimum amount of $250,000. Financing shall not include (i) the issuance or sale of shares of Common Stock or
options to purchase Common stock to employees, officers, directors or consultants for the primary purpose of soliciting or retaining their services in such amount as shall have been approved by the Board of Directors, (ii) the issuance or sale
of Securities to leasing entities or financial institutions in connection with commercial leasing or borrowing transactions approved by the Board of Directors, (iii) the issuance or sale of Securities to third party providers of goods or
services in connection with 

  
 20 

 
transactions approved by the Board of Directors; (iv) the sale of Securities in a registered public offering, (v) any issuances of Securities in connection with any stock split, stock
dividend or recapitalization by the Company, (vi) the issuance of Securities at a price (on an as converted to Common Stock basis) below the original issue price of the Company’s Series E Preferred Stock (as adjusted for stock splits,
recapitalizations and like events) in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or any joint venture or strategic alliance, if such issuance is approved unanimously
by the Board of Directors, (vii) the issuance of Securities at a price (on an as converted to Common Stock basis) at or above the original issue price of the Company’s Series E Preferred Stock (as adjusted for stock splits,
recapitalizations and like events) in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or any joint venture or strategic alliance, if such issuance is approved by the
Board of Directors, (viii) the issuance of Securities at a price (on an as converted to Common Stock basis) below the original issue price of the Company’s Series E Preferred Stock (as adjusted for stock splits, recapitalizations and like
events) in connection with the acquisition of another corporation by the Company by merger, consolidation, or purchase of all or substantially all of the assets or shares of such corporation unanimously approved by the Board of Directors,
(ix) the issuance of Securities at a price (on an as converted to Common Stock basis) at or above the original issue price of the Company’s Series E Preferred Stock (as adjusted for stock splits, recapitalizations and like events) in
connection with the acquisition of another corporation by the Company by merger, consolidation, or purchase of all or substantially all of the assets or shares of such corporation approved by the Board of Directors; (x) shares of Series E
Preferred Stock issued pursuant to the terms of the Prior Purchase Agreement or the 2009 Purchase Agreement; and (xi) interest-bearing convertible promissory notes in the aggregate principal amount of $8 million issued or issuable pursuant to
the CNPA and/or the CNA and any Securities issued on conversion thereof. 
 3.5    Termination of Right
of First Offer.  The right of first offer contained in this Section shall not apply to and shall terminate upon the closing of an Initial Public Offering. The right of first offer granted under this Section 3 is transferable
to transferees of at least 750,000 shares of Registrable Securities (as adjusted for stock splits, combinations and the like) or to Affiliates. 
 SECTION 4 
 Right of First Offer with Respect to Founder Shares

 4.1    Notice of Sales.  Should a Founder (a “Seller”) propose to
accept one or more bona fide offers (collectively, the “Purchase Offer”) from any persons (“Purchasers”) to purchase Founders Shares from such Seller (other than as set forth 4.2(d) hereof), then such Seller shall,
promptly after exercise or termination of any rights of first refusal held by the Company, deliver a notice (the “Notice”) to the Company and all Investors holding more than 750,000 shares of Eligible Securities (“Eligible
Investors”). 
 4.2    Purchase Right.  Each Eligible Investor shall have the
right, exercisable upon written notice to such Seller within ten (10) business days after receipt of the Notice, to purchase Founders Shares on the terms and conditions specified in the Purchase Offer. To the extent an Eligible Investor
exercises its right to purchase such shares in accordance with the terms and conditions set forth below, the number of shares of stock which such Seller may sell to the 

  
 21 

 
Purchasers pursuant to the Purchase Offer shall be correspondingly reduced. The purchase right of each Eligible Investor shall be subject to the following terms and conditions: 

(a)    Calculation of Shares.  Each Eligible Investor may purchase all or any part of that number
of Founder Shares equal to the number obtained by multiplying (i) the aggregate number of Founders Shares covered by the Purchase Offer by (ii) a fraction, the numerator of which is the number of shares of Common Stock of the Company at
the time owned by such Eligible Investor and the denominator of which is the number of shares of Common Stock of the Company then outstanding. For the purposes of the foregoing calculations, all outstanding options and warrants shall be deemed to be
exercised and all Preferred Stock shall be deemed to have been converted into Common Stock at the prevailing conversion rate. 

(b)    Delivery of Consideration.  Each Eligible Investor may effect its purchase right by promptly
delivering to such Seller a written notice and a check or wire transfer equal to the purchase price specified in the Purchase Offer for the number of shares the Eligible Investor desires to purchase pursuant to this Section 4.2. 

(c)    Certificate.  Within ten (10) business days of receipt of Eligible Investor’s
funds pursuant to Section 4.2(c), Seller shall deliver to such Eligible Investor a certificate or certificates representing the shares of Founder Shares purchased by such Eligible Investor. 

(d)    Permitted Transactions.  The participation rights in this Section 4 shall not pertain
or apply to: 
 (i)      Any transfer to a revocable grantor trust with respect to which the
Founder and members of his family are the sole beneficiaries; 
 (ii)     Any repurchase of Founders
Shares by the Company; 
 (iii)    Any exercise by the Company of a right or remedy under the terms of any
loan, security or stock pledge agreement where the Founders Shares serve as security for a loan made by the Company; 

(iv)     Any transfer to any ancestors or descendants or spouse of a Founder or to a trustee for their benefit
or to a custodian for the benefit of a Founders’ issue; or 
 (v)      Any bona fide gift;

 provided, however, that such Founder shall inform the Eligible Investors of such transfer or gift (other than a transfer pursuant to clause
(ii) or (iii)) prior to effecting it and the transferee or donee (if other than the Company) shall furnish the Company and the Eligible Investors with a written agreement to be bound by and comply with all applicable provisions of this
Agreement. 
 4.3    Sale of Securities by Founder.  Within 60 days of the expiration of
the period described in the first paragraph of Section 4.2, any Founders Shares covered by the Purchase Offer which the Eligible Investors have not elected to purchase may be sold by the Seller to the Purchasers on the terms and conditions of
the Purchase Offer. If the Seller does not complete the sale of all 

  
 22 

 
Founders Shares covered by the Purchase Offer within such period, the rights of the Eligible Investors with respect to any such unsold Founders Shares shall be deemed to be revived. 

4.4     Termination and Transfer.  The restrictions imposed and rights granted by this
Section 4 shall not apply to and shall terminate immediately prior to the closing of the Company’s Initial Public Offering. Securities received pursuant to any stock dividend, stock split, recapitalization, or exercise of a conversion
right shall be subject to this Section 4 to the same extent as the shares of the Company with respect to which they were issued. The right of first offer granted under this Section 4 is transferable to transferees of at least 750,000
shares of Registrable Securities (as adjusted for stock splits, combinations and the like) or to Affiliates. 
 4.5
    Prohibited Transfer.  Any attempt by a Founder to transfer Founders Shares in violation of Section 4 hereof shall be void and the Company agrees it will not effect such a transfer nor will it treat any
alleged transferee(s) as the holder of such shares, without the written consent of two-thirds (2/3) in interest of the Eligible Investors. 
 SECTION 5  
 Right of Co-Sale 

5.1     Notice of Sales.  Should a Founder (a “Seller”) propose to accept one or
more bona fide offers (collectively, the “Purchase Offer”) from any persons (“Purchasers”) to purchase Founders Shares from such Seller (other than as set forth 5.2(d)), then such Seller shall, promptly after
exercise or termination of any rights of first refusal held by the Company or the Eligible Investors, deliver a notice (the “Notice”) to the Company and all Eligible Investors describing the terms and conditions of the Purchase
Offer. 
 5.2     Participation Right.  Each Eligible Investor shall have the right,
exercisable upon written notice to such Seller within fifteen (15) business days after receipt of the Notice, to participate in such Seller’s sale of stock pursuant to the specified terms and conditions of such Purchase Offer. To the
extent an Eligible Investor exercises such right of participation in accordance with the terms and conditions set forth below, the number of shares of stock which such Seller may sell pursuant to such Purchase Offer shall be correspondingly reduced.
The right of participation of each Eligible Investor shall be subject to the following terms and conditions: 

(a)    Calculation of Shares.  Each Eligible Investor may sell all or any part of that number of
shares of Common Stock of the Company equal to the number obtained by multiplying (i) the aggregate number of Founders Shares covered by the Purchase Offer by (ii) a fraction, the numerator of which is the number of shares of Common Stock
of the Company at the time owned by such Eligible Investor and the denominator of which is the number of shares of Common Stock of the Company then outstanding. For the purposes of the foregoing calculations, all outstanding options and warrants
shall be deemed to be exercised and all Preferred Stock shall be deemed to have been converted into Common Stock at the prevailing conversion rate. 
 (b)    Delivery of Certificates.  Each Eligible Investor may effect its participation in the sale by delivering to such Seller for transfer to the Purchaser(s) one or
more 

  
 23 

 
certificates, properly endorsed for transfer, which represent at least the number of shares of Common Stock which such Eligible Investor elects to sell pursuant to this Section 5.2.

 (c)    Transfer.  The stock certificate or certificates which the Eligible Investor
delivers to such Seller pursuant to Section 5.2 shall be delivered by the Seller to the Purchaser(s) in consummation of the sale of the Securities pursuant to the terms and conditions specified in the Notice, and such Seller shall promptly
thereafter remit to such Eligible Investor that portion of the sale proceeds to which such Eligible Investor is entitled by reason of its participation in such sale. 
 (d)    Permitted Transactions.  The participation rights in this Section 5 shall not pertain or apply to: 

(i)      Any transfer to a revocable grantor trust with respect to which the Seller and members of his
family are the sole beneficiaries; 
 (ii)     Any repurchase of Founders Shares by the Company;

 (iii)    Any exercise by the Company of a right or remedy under the terms of any loan, security or stock
pledge agreement where the Founders Shares serve as security for a loan made by the Company; 

(iv)     Any transfer to any ancestors or descendants or spouse of a Founder or to a trustee for their benefit
or to a custodian for the benefit of a Founders’ issue; or 
 (v)      Any bona fide gift;

 provided, however, that such Founder shall inform the Eligible Investors of such transfer or gift (other than a transfer pursuant to clause
(ii) or (iii)) prior to effecting it and the transferee or donee (if other than the Company) shall furnish the Company and the Eligible Investors with a written agreement to be bound by and comply with all applicable provisions of this
Agreement. 

  
 24 

 5.3     Sale of Securities by Founder.  Within 45 days
of the expiration of the period described in the first paragraph of Section 5.2, any Founders Shares covered by the Purchase Offer which the Eligible Investors have not elected to purchase may be sold by the Seller to the Purchasers on the
terms and conditions of the Purchase Offer. If the Seller does not complete the sale of all Founders Shares covered by the Purchase Offer within such period, the rights of the Eligible Investors with respect to any such unsold Founders Shares shall
be deemed to be revived. 
 5.4     Termination and Transfer.  The restrictions imposed
and rights granted by this Section 5 shall not apply to and shall terminate immediately prior to the closing of the Company’s Initial Public Offering. Securities received pursuant to any stock dividend, stock split, recapitalization, or
exercise of a conversion right shall be subject to this Section 5 to the same extent as the shares of the Company with respect to which they were issued. The co-sale right granted under this Section 5 is transferable to transferees of at
least 750,000 shares of Registrable Securities (as adjusted for stock splits, combinations and the like) or to Affiliates. 

5.5     Prohibited Transfers. 
 (a)    In the event any Founder should sell any Founders Shares in contravention of the co-sale rights of the Investors under Section 5 (a “Prohibited Transfer”),
the Investors, in addition to such other remedies as may be available at law, in equity or hereunder, shall have the put option provided below, and the Founder shall be bound by the applicable provisions of such option. 

(b)    In the event of a Prohibited Transfer, each Eligible Investor shall have the right to sell to the Founder the
type and number of shares of Common Stock equal to the number of shares that such Eligible Investor would have been entitled to transfer to the third-party transferee(s) under Section 5.2 hereof had the Prohibited Transfer been effected
pursuant to and in compliance with the terms thereof. Such sale shall be made on the following terms and conditions: 

(i)      The price per share at which the shares are to be sold to the Founder shall be equal to the price
per share paid by the third-party transferee(s) to the Founder in the Prohibited Transfer. Such price per share shall be paid to the Eligible Investor in cash if the Founder received cash for his shares. If the Founder did not receive cash but
received other property instead, the price per share to be paid to the Eligible Investor shall be paid (A) in the form of the property received by the Founder for his shares, or (B) in cash equal to the fair market value of the property
received by such Founder as determined in good faith by the Company’s Board of Directors, at the option of the Eligible Investor. The Founder shall also reimburse each Eligible Investor for any and all fees and expense, including legal fees and
expenses, incurred pursuant to the exercise or the attempted exercise of the Eligible Investor’s rights under Section 5. 
 (ii)     Within thirty (30) days after the later of the dates on which the Eligible Investor (A) received notice of the Prohibited Transfer or (B) otherwise became
aware of the Prohibited Transfer, each Eligible Investor shall, if exercising the option created hereby, deliver to the Founder the certificate or certificates representing shares to be sold, each certificate to be properly endorsed for transfer.

  
 25 

 (iii)    The Founder shall, upon receipt of the certificate or
certificates for the shares to be sold by an Eligible Investor pursuant to this Section 5, pay the aggregate purchase price therefor and the amount of reimbursable fees and expenses, as specified in subparagraph 5.5(b)(i), in cash or by other
means acceptable to the Eligible Investor. 
 (c)    Notwithstanding the foregoing, any attempt by a
Founder to transfer Founders Shares in violation of Section 5 hereof shall be void and the Company agrees it will not effect such a transfer nor will it treat any alleged transferee(s) as the holder of such shares, without the written consent
of two-thirds (2/3) in interest of the Eligible Investors. 
 SECTION 6  

Miscellaneous 
 6.1     Governing Law; Jurisdiction.  This Agreement shall be construed in accordance with, and governed in all respects by, the laws of the State of California, as
applied to agreements entered into, and to be performed entirely in such state, between residents of such state. 
 The parties
hereto agree to submit to the jurisdiction of the federal and state courts of San Mateo County, California with respect to the breach or interpretation of this Agreement or the enforcement of any and all rights, duties, liabilities, obligations,
powers, and other relations between the parties arising under this Agreement. 

  
 26 

 6.2    Successors and Assigns.  Except as otherwise
provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 
 6.3    Notices, Etc.  All notices and other communications required or permitted hereunder, shall be in writing and shall be sent by facsimile personally delivered,
mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by a nationally-recognized overnight courier, addressed (a) if to an Investor, at Investor’s facsimile number or address as set forth
in the records of the Company or (b) if to any other holder of any Eligible Securities, at such address as such holder shall have furnished the Company in writing, or, until any such holder so furnishes an address to the Company, then to and at
the address of the last holder of such Eligible Securities who has so furnished an address or facsimile number to the Company, or (c) if to a Founder, at such Founder’s facsimile number or address set forth on Exhibit B hereto,
or a such other address as such Founder shall have furnished to the Company in writing, or (d) if to the Company, at its facsimile number or address set forth on the signature page hereto addressed to the attention of the Corporate Secretary,
or at such other address as the Company shall have furnished to the Investors. Any such notice or communication shall be deemed to have been received (A) in the case of personal delivery, on the date of such delivery, (B) in the case of a
nationally-recognized overnight courier, on the next business day after the date when sent, (C) in the case of mailing, on the third business day following that on which the piece of mail containing such communication is posted and (D) in
the case of delivery via facsimile, one (1) business day after the date of transmission provided that said transmission is confirmed telephonically on the date of transmission. 

6.4    Delays or Omissions.  No delay or omission to exercise any right, power or remedy accruing
to any holder of any Eligible Securities upon any breach or default of the Company under this Agreement shall impair any such right, power or remedy of such holder, nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any holder of any breach or default under this Agreement, or any waiver on the part of any holder of any provisions or conditions of this Agreement, must be in writing and shall be
effective only to the extent specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to any holder, shall be cumulative and not alternative. 

6.5    Third Parties.  Nothing in this Agreement, express or implied, is intended to confer upon
any party, other than the parties hereto, and their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.6    Severability.  If one or more provisions of this Agreement are held to be unenforceable
under applicable law, portions of such provisions, or such provisions in their entirety, to the extent necessary, shall be severed from this Agreement, and the balance of this Agreement shall be enforceable in accordance with its terms. 

  
 27 

 6.7    Amendment and Waiver.  Any provision of this
Agreement may be amended or waived with the written consent of the Company and the Holders of at least two-thirds of the outstanding shares of the Registrable Securities then held by Holders (assuming the exercise or conversion of all outstanding
Eligible Securities); provided, however, (i) that in the event such amendment or waiver adversely affects the rights and/or obligations of the Founders under this Agreement in a different manner than the other Holders, such
amendment or waiver shall also require written consent of the Founders holding a majority of the then outstanding Founders Shares, (ii) that in the event such amendment or waiver adversely affects the rights and/or obligations of Lehman,
EuclidSR, Piper Jaffray, GE Capital, Interwest, Alliance, Wasatch, BMSIF or the October 2007 Representative under Section 2.4 of this Agreement, such amendment or waiver shall not be effective as to Lehman, EuclidSR, Piper Jaffray, GE Capital,
Interwest, Alliance, Wasatch, BMSIF or the October 2007 Representative, as the case may be, without the written consent of such party, and (iii) that in the event such amendment or waiver adversely affects the rights and/or obligations of
Warrantholders under this Agreement in a different manner than the other Holders, such amendment or waiver shall also require the written consent of Warrantholders holding a majority of the then outstanding Warrant Shares. Notwithstanding the
foregoing, any purchaser of Series E Preferred Stock pursuant to the 2009 Purchase Agreement may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and such purchaser shall be
deemed a Holder and an Investor hereunder. The parties agree that Exhibit A shall be updated automatically without any formal amendment to reflect the addition of any such additional party. Any amendment or waiver effected in accordance
with this paragraph shall be binding upon each Holder, the Founders, the holder of the Other Shares, Warrantholders and the Company. In addition, the Company may waive performance of any obligation owing to it, as to some or all of the Holders, or
agree to accept alternatives to such performance, without obtaining the consent of any other Holder. In the event that an underwriting agreement is entered into between the Company and any Holder, and such underwriting agreement contains terms
differing from this Agreement, as to any such Holder the terms of such underwriting agreement shall govern. 

6.8    Rights of Holders.  Each Holder shall have the absolute right to exercise or refrain from
exercising any right or rights that such holder may have by reason of this Agreement, including, without limitation, the right to consent to the waiver or modification of any obligation under this Agreement, and such holder shall not incur any
liability to any other holder of any Securities as a result of exercising or refraining from exercising any such right or rights. 
 6.9    Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such
counterparts, and all of which together shall constitute one instrument. 
 6.10  Titles and
Subtitles.  The titles of the paragraphs and subparagraphs of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

6.11  Amendment and Restatement of Prior Agreement.  The undersigned Prior Investors who in the aggregate
hold at least two-thirds of the outstanding Registrable Securities (as defined in the Prior Agreement) and the undersigned Founders hereby amend and restate the Prior Agreement pursuant to Section 6.7 thereof. 

  
 28 

 6.12  Waiver of Right of First Offer.  The undersigned Prior
Investors who in the aggregate hold at least two-thirds of the outstanding Registrable Securities (as defined in the Prior Agreement) hereby waive on behalf of all Prior Investors any rights of participation or notice under Section 3 of this
Agreement and the Prior Agreement with respect to the securities sold pursuant to the 2009 Purchase Agreement. By its execution below, Lighthouse waives any right of participation or notice under Section 3 of this Agreement and Section 3
of the Prior Agreement with respect to securities sold under the 2009 Purchase Agreement. 
 6.13  Aggregation of
Stock.  All shares of Eligible Securities held or acquired by Affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

6.14  Jury Trial 
 . EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE)
ARISING OUT OF OR RELATED TO THIS AGREEMENT. 
 * * * * * 

  
 29 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	COMPANY:	 		 		 	
		 		 	FLUIDIGM CORPORATION
				
		 		 	By:	 	  /s/ Gajus V. Worthington

		 		 		 	Gajus V. Worthington,
		 		 		 	President and Chief Executive Officer
			
		 		 	Address:
				
		 		 		 	7000 Shoreline Court, Suite 100
		 		 		 	South San Francisco, CA 94080

[Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	FOUNDERS:	 		 	
			
		 		 	 /s/ Gajus V. Worthington

		 		 	Gajus V. Worthington
			
		 		 	 /s/ Stephen R. Quake

		 		 	Stephen R. Quake

 [Ninth Amended
and Restated Investor Rights Agreement of Fluidigm Corporation]  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	ARTEMIS HEALTH, INC.
		 		 	a Delaware Corporation
				
		 		 	By:	 	 Phyllis Whiteley

				
		 		 	Name:	 	 Phyllis Whiteley

				
		 		 	Title:	 	 Chief Executive Officer

[Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation]  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	VERSANT AFFILIATES FUND 1-A, L.P.
		 		 	VERSANT AFFILIATES FUND 1-B, L.P.
		 		 	VERSANT SIDE FUND I, L.P.
		 		 	VERSANT VENTURE CAPITAL I, L.P.
				
		 		 	By:	 	Versant Ventures I, LLC
		 		 		 	its General Partner
				
		 		 	By:	 	 /s/ Samuel D. Colella

				
		 		 	Name:	 	 Samuel D. Colella

				
		 		 	Title:	 	 Managing Director

[Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation]  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	EUCLIDSR PARTNERS, L.P.
				
		 		 	By:	 	EuclidSR Associates, L.P.,
		 		 		 	its General Partner
				
		 		 	By:	 	 /s/ Raymond J. Whitaker

				
		 		 	Name:	 	 Raymond J. Whitaker

				
		 		 	Title:	 	 General Partner

			
		 		 	EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.
				
		 		 	By:	 	EuclidSR Biotechnology Associates, L.P.,
		 		 		 	its General Partner
				
		 		 	By:	 	 /s/ Raymond J. Whitaker

				
		 		 	Name:	 	 Raymond J. Whitaker

				
		 		 	Title:	 	 General Partner

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

									
	INVESTORS:	 		 	BIOMEDICAL SCIENCES INVESTMENT FUND PTE 
LTD
					
		 		 	By:	 	 /s/ Chu Swee Yeok
	 	
					
		 		 	Name:	 	 Chu Swee Yeok
	 	
					
		 		 	Title:	 	 Director
	 	
			
		 		 	SINGAPORE BIO-INNOVATIONS PTE LTD
					
		 		 	By:	 	 /s/ Ho Siu Gie
	 	
					
		 		 	Name:	 	 Ho Siu Gie
	 	
					
		 		 	Title:	 	 Director
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	WS INVESTMENT COMPANY, LLC (2009A)
				
		 		 	By:	 	 /s/ James A. Terranova

				
		 		 	Name:	 	  

				
		 		 	Title:	 	  

			
		 		 	WS INVESTMENT COMPANY, LLC (2009C)
				
		 		 	By:	 	 /s/ James A. Terranova

				
		 		 	Name:	 	  

				
		 		 	Title:	 	  

			
		 		 	WS INVESTMENT COMPANY, LLC (99B)
				
		 		 	By:	 	 /s/ James A. Terranova

				
		 		 	Name:	 	  

				
		 		 	Title:	 	  

			
		 		 	WS INVESTMENT COMPANY, LLC (2000B)
				
		 		 	By:	 	 /s/ James A. Terranova

				
		 		 	Name:	 	  

				
		 		 	Title:	 	  

			
		 		 	WS INVESTMENT COMPANY, LLC (2001D)
				
		 		 	By:	 	 /s/ James A. Terranova

				
		 		 	Name:	 	  

				
		 		 	Title:	 	  

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

									
	INVESTORS:	 		 	ALLOY VENTURES 2005, L.P.
					
		 		 	By:	 	Alloy Ventures 2005, LLC	 	
		 		 		 	its General Partner	 	
					
		 		 	By:	 	 /s/ Craig C. Taylor
	 	
					
		 		 	Name:	 	 Craig C. Taylor
	 	
				
		 		 	Title:	 	 Managing Member of Alloy Ventures 2005 LLC

		 		 		 	 Managing Member of Alloy Ventures 2005, L.P.

			
		 		 	ALLOY VENTURES 2002, L.P.
		 		 	ALLOY PARTNERS 2002, L.P.
					
		 		 	By:	 	Alloy Ventures 2002, LLC	 	
		 		 		 	its General Partner	 	
					
		 		 	By:	 	 /s/ Craig C. Taylor
	 	
					
		 		 	Name:	 	 Craig C. Taylor
	 	
				
		 		 	Title:	 	 Managing Member of Alloy Ventures 2002 LLC

		 		 		 	 Managing Member of Alloy Partners 2002, L.P.

		 		 		 	 and Alloy Ventures 2002, L.P.

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 		 	
			
		 		 	 /s/ Bruce Burrows

		 		 	BRUCE BURROWS

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	ROBERT F. KORNEGAY, JR. REVOCABLE TRUST
		 		 	U/D/T DATED MAY 27, 2004,
		 		 	ROBERT F. KORNEGAY, JR., TRUSTEE
				
		 		 	By:	 	 /s/ Robert F. Kornegay

				
		 		 	Name:	 	 Robert F. Kornegay

				
		 		 	Title:	 	 Trustee

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	ALLIANCEBERNSTEIN VENTURE FUND I, L.P.
				
		 		 	By:	 	 AllianceBernstein ESG Venture Management,
 L.P.,its general partner

				
		 		 	By:	 	 AllianceBernstein Global Derivatives
 Corporation, its general partner

				
		 		 	By:	 	 /s/ Mona Bhalla

				
		 		 	Name:	 	 Mona Bhalla

				
		 		 	Title:	 	 Vice President

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	SIGHTLINE HEALTHCARE FUND III, L.P.
				
		 		 	By:	 	 /s/ Maureen Harder

				
		 		 	Name:	 	 Maureen Harder

				
		 		 	Title:	 	 Managing Director

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	CROSS CREEK CAPITAL, L.P.
				
		 		 	By:	 	 Cross Creek Capital GP, L.P.,

its Sole General Partner

				
		 		 	By:	 	 Cross Creek Capital, LLC,

its Sole General Partner

				
		 		 	By:	 	 Wasatch Advisors, Inc.,
 its
Sole Member

				
		 		 	By:	 	 Daniel Thurber

				
		 		 	Name:	 	 /s/ Daniel Thurber

				
		 		 	Title:	 	 Vice President

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	CROSS CREEK CAPITAL EMPLOYEES’ FUND, 
L.P.
				
		 		 	By:	 	 Cross Creek Capital GP, L.P.,

its Sole General Partner

				
		 		 	By:	 	 Cross Creek Capital, LLC,

its Sole General Partner

				
		 		 	By:	 	 Wasatch Advisors, Inc.,
 its
Sole Member

				
		 		 	By:	 	 /s/ Daniel Thurber

				
		 		 	Name:	 	 Daniel Thurber

				
		 		 	Title:	 	 Vice President

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 	WASATCH FUNDS, INC.
		 		 	Wasatch Small Cap Growth Fund
				
		 		 	By:	 	Wasatch Advisors, Inc.,
		 		 		 	its Investment Adviser
				
		 		 	By:	 	 /s/ Daniel Thurber

				
		 		 	Name:	 	 Daniel Thurber

				
		 		 	Title:	 	 Vice President

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

											
	INVESTORS:	 		 		 		 		 	
	 	 	 	 	SMALLCAP WORLD FUND, INC.	 	 	 	 
				
		 		 	By:	 	Capital Research and Management Company,
		 		 		 	its investment adviser	 		 	
						
		 		 	By:	 	 /s/ Michael J. Downer
	 		 	
						
		 		 	Name:	 	 Michael J. Downer
	 		 	
						
		 		 	Title:	 	 Senior Vice President and Secretary
	 		 	

  

											
		 		 	Approved for Signature	 	 	 		 	
		 		 		 	L2e	 		 	
		 		 	by CRMC Legal Dept.	 	 	 		 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 		 		 	
		 		 	FIDELITY CONTRAFUND:
		 		 	FIDELITY ADVISOR NEW INSIGHTS FUND
				
		 		 	By:	 	 /s/ Jeffrey Christian

				
		 		 	Name:	 	 Jeffrey Christian

				
		 		 	Title:	 	 Deputy Treasurer

			
		 		 	 FIDELITY CONTRAFUND: FIDELITY

CONTRAFUND

				
		 		 	By:	 	 /s/ Jeffrey Christian

				
		 		 	Name:	 	 Jeffrey Christian

				
		 		 	Title:	 	 Deputy Treasurer

			
		 		 	VARIABLE INSURANCE PRODUCTS FUND II:
		 		 	CONTRAFUND PORTFOLIO
				
		 		 	By:	 	 /s/ Jeffrey Christian

				
		 		 	Name:	 	 Jeffrey Christian

				
		 		 	Title:	 	 Deputy Treasurer

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	IN-Q-TEL, INC.
			
		 	By:	 	 /s/ Matt Strottman

			
		 	Name:	 	 Matt Strottman

			
		 	Title:	 	 CFO

		
		 	IN-Q-TEL EMPLOYEES FUND, LLC
			
		 	By:	 	 /s/ Matt Strottman

			
		 	Name:	 	 Matt Strottman

			
		 	Title:	 	 CFO of In-Q-Tel, Inc., the manager

			
		 		 	of the fund.

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	LEERINK SWANN HOLDINGS, LLC
				
		 	By:	 	 [illegible]
	 	
				
		 	Name:	 	  
	 	
				
		 	Title:	 	  
	 	
		
		 	LEERINK SWANN CO-INVESTMENT FUND, LLC
				
		 	By:	 	 /s/ Joseph R. Gentile
	 	
				
		 	Name:	 	 Joseph R. Gentile
	 	
				
		 	Title:	 	 Management Committee Member
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	TECHNOGEN LIQUIDATING TRUST	 	
				
		 	By:	 	 /s/ Isaac Stein
	 	
				
		 	Name:	 	 Isaac Stein
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	MARKWELL PARTNERS
			
		 	By:	 	 [illegible]

			
		 	Name:	 	 [illegible]

			
		 	Title:	 	 Managing Partner

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	KILEY REVOCABLE TRUST
			
		 	By:	 	 /s/ Thomas D. Kiley

			
		 	Name:	 	 Thomas D. Kiley

			
		 	Title:	 	 Trustee

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 STANLEY D. HAYDEN, AND HIS
SUCCESSOR(S),
 AS THE TRUSTEE OF
THE STANLEY D. HAYDEN
 FAMILY TRUST

				
		 	By:	 	 /s/ Stanley D. Hayden
	 	
				
		 	Name:	 	 Stanley D. Hayden
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	J.F. SHEA CO., INC. AS NOMINEE 1999-114
			
		 	By:	 	 /s/ Ronald L. Lakey

			
		 	Name:	 	 Ronald L. Lakey

			
		 	Title:	 	 Vice President

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Fredrick Stern

	FREDRICK STERN

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ George S. Taylor

	GEORGE S. TAYLOR

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ James W. Larrick M.D.

	JAMES W. LARRICK M.D.

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Stephen L. Parry

	STEPHEN L. PARRY

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Thomas J. Parry

	THOMAS J. PARRY

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Peter B. Dervan

	PETER B. DERVAN

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ John M. Harland

	JOHN M. HARLAND

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Matthew Frank

	MATTHEW FRANK

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Alejandro Berenstein M.D.

	ALEJANDRO BERENSTEIN M.D.

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Patrick Tenney

	PATRICK TENNEY

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Herbert L. Heyneker

	HERBERT L. HEYNEKER

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

									
	INVESTORS:	 	 STEPHEN J. WEISS AND URSULA G.
WEISS,
 TRUSTEES OF THE WEISS FAMILY
TRUST 1996
 TRUST

					
		 	By:	 	 /s/ Stephen J. Weiss
	 		 	
					
		 	Name:	 	 Stephen J. Weiss
	 		 	
					
		 	Title:	 	 Trustee
	 		 	
			
		 	 /s/ Stephen J. Weiss
	 	
		 	STEPHEN J. WEISS	 		 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Paul Machle

	PAUL MACHLE

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Fred St. Goar

	FRED ST. GOAR

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Gary R. Bang

	GARY R. BANG

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Michael H. McKay

	MICHAEL H. MCKAY

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Alfred J. Mandel

	ALFRED J. MANDEL

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Peter S. Heinecke

	PETER S. HEINECKE

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Pauline van Ysendoorn

	PAULINE VAN YSENDOORN

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
 INVESTORS: 
  

	
	 /s Erik Van Der Burg

	ERIK VAN DER BURG

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	CLARK-BOYD FAMILY TRUST	 	
				
		 	By:	 	 /s/ Kenneth A. Clark
	 	
				
		 	Name:	 	 Kenneth A. Clark
	 	
				
		 	Title:	 	  
	 	
		
		 	 /s/ Kenneth A. Clark

		 	KENNETH A. CLARK

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	ANALIZA, INC.
			
		 	By:	 	 /s/ Arnon Chait

			
		 	Name:	 	 Arnon Chait

			
		 	Title:	 	 President

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:	 	
		
		 	 /s/ John E. Strobeck PhD M.D.

		 	JOHN E. STROBECK PHD M.D.

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	 ADVISORY TRUST COMPANY OF
DELAWARE,
 CUSTODIAN FOR SANDRA KAY ROTH
IRA

			
		 	By:	 	 /s/ Ramona Cisneros

			
		 	Name:	 	 Ramona Cisneros

			
		 	Title:	 	 Trust Administrator

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	NR07, LLC
			
		 	By:	 	 /s/ Sumner Rosenberg

			
		 	Name:	 	 Sumner Rosenberg

			
		 	Title:	 	 Manager

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	TTC FUND I, LLC
			
		 	By:	 	 /s/ Philip H. Albert

			
		 	Name:	 	 Philip H. Albert

			
		 	Title:	 	  

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 ERIK T. ENGELSON, TRUSTEE OF THE
ERIK T.
 ENGELSON TRUST UTD DATED
MARCH 29, 2000

				
		 	By:	 	 /s/ Erik T. Engelson
	 	
				
		 	Name:	 	 Erik T. Engelson
	 	
				
		 	Title:	 	 Trustee
	 	
			
		 	 ERIK T. ENGELSON, TRUSTEE OF
THE
 ELISABETH NORTH KUECHLER ENGELSON

TRUST UTA DATED JANUARY 17, 2001
	 	
				
		 	By:	 	 /s/ Erik T. Engelson
	 	
				
		 	Name:	 	 Erik T. Engelson
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 ROBERT D. MCCULLOCH AND KATHLEEN
M.
 MCCULLOCH, TRUSTEES OR THEIR

SUCCESSOR(S) OF THE ROBERT D.
MCCULLOCH
 AND KATHLEEN M. MCCULLOCH
FAMILY
 TRUST DATED NOVEMBER 19, 1997

				
		 	By:	 	 /s/ Robert D. McCulloch
	 	
				
		 	Name:	 	 Robert D. McCulloch
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 ADVISORY TRUST COMPANY OF
DELAWARE,
 CUSTODIAN FOR FRANK RUDERMAN ROTH
IRA

				
		 	By:	 	 /s/ Ramona Cisneros
	 	
				
		 	Name:	 	 Ramona Cisneros
	 	
				
		 	Title:	 	 Trust Adminstrator
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	THE CONDON FAMILY TRUST
			
		 	By:	 	 /s/ Thomas J. Condon

			
		 	Name:	 	 Thomas J. Condon

			
		 	Title:	 	 TTE

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	HEALTH CARE ADMINISTRATION COMPANY
				
		 	By:	 	 /s/ Gary L. Bowers
	 	
				
		 	Name:	 	 Gary L. Bowers
	 	
				
		 	Title:	 	 President
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	GLAXOSMITHKLINE LLC
			
		 	By:	 	 /s/ William J. Mosher

			
		 	Name:	 	 William J. Mosher

			
		 	Title:	 	 Vice President & Secretary

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	BURWEN FAMILY TRUST U/D/T DATED 9/30/88
				
		 	By:	 	 /s/ David M. Burwen
	 	
				
		 	Name:	 	 David M. Burwen
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 MICHAEL J. REARDON TRUST AGREEMENT

DATED JUNE 5, 1996

				
		 	By:	 	 /s/ Michael J. Reardon
	 	
				
		 	Name:	 	 Michael J. Reardon
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 HENRY P. MASSEY, JR. TTEE MASSEY
FAMILY
 TRUST U/A DTD 7/06/88

				
		 	By:	 	 /s/ Henry P. Massey
	 	
				
		 	Name:	 	 Henry P. Massey
	 	
				
		 	Title:	 	 Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	THE V FOUNDATION FOR CANCER RESEARCH
				
		 	By:	 	 /s/ Nick Valvano
	 	
				
		 	Name:	 	 Nick Valvano
	 	
				
		 	Title:	 	 CEO
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	 LEO J. PARRY, JR. AND ROBERTA J.
PARRY
 TTEES PARRY FAMILY REVOCABLE TRUST

DTD 01/22/97

			
		 	By:	 	 /s/ Leo J. Parry and Roberta J. Parry

			
		 	Name:	 	 Leo J. Parry and Roberta J. Parry

			
		 	Title:	 	 Trustees

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 WILLIAM S. BROWN AND BARBARA G.
BROWN,
 OR THEIR SUCCESSORS, AS TRUSTEES
OF THE
 BROWN FRT DTD 3/10/99

				
		 	By:	 	 /s/ William S. Brown
	 	
				
		 	Name:	 	 William S. Brown
	 	
				
		 	Title:	 	 Co-Trustee
	 	
				
		 	By:	 	 /s/ Barbara G. Brown
	 	
				
		 	Name:	 	 Barbara G. Brown
	 	
				
		 	Title:	 	 Co-Trustee
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
	INVESTORS:	 	 2008 STEPHEN RONALD QUAKE AND
ATHINA
 PEIOU-QUAKE REVOCABLE TRUST
DATED
 AUGUST 14, 2008

				
		 	By:	 	 /s/ Stephen Quake
	 	
				
		 	Name:	 	 Stephen Quake
	 	
				
		 	Title:	 	  
	 	

  
 [Ninth
Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 EXHIBIT A 
 NEW INVESTORS 
 New Investors 

 
 Artemis Health, Inc. 

2008 Stephen Ronald Quake and Athina Peiou-Quake Revocable Trust dated August 14, 2008 
 ABT Holding Company 
 Advisory Trust Company of Delaware, Custodian for Frank Ruderman Roth Ira

 Advisory Trust Company of Delaware, Custodian for Sandra Kay Roth IRA 
 Alejandro Berenstein, M.D. 
 Allan May, Trustee Intervivos Trust dated 5/14/91 

Alfred J. Mandel 
 AllianceBernstein Venture Fund
I, L.P. 
 Alloy Partners 2002, L.P. 

Alloy Ventures 2002, L.P. 
 Alloy Ventures 2005,
L.P. 
 Analiza, Inc. 
 Biomedical
Sciences Investment Fund Pte Ltd 
 Bradford S. Goodwin and Cathy W. Goodwin as Trustees of The Goodwin Family Trust u/a/d 7/30/97

 Bruce Burrows 
 Burwen Family Trust
u/d/t dated 9/30/08 
 Clark/Boyd Trust 

Cross Creek Capital, L.P. 
 Cross Creek
Employees’ Fund, L.P. 
 David Scott Frampton and Gaja Roberta Frampton, as Trustees of the Frampton Family Trust dtd 4/25/03 

Dwayne Hardy 
 Edward R. Lemoure 

Erik Van Der Burg 
 Erik T. Engelson,
Trustee of the Elisabeth North Kuechler Engelson Trust uta dated January 17, 2001 
 Erik T. Engelson, Trustee of the Erik T.
Engelson Trust u/t/d dated March 29, 2000 
 EuclidSR Biotechnology Partners, L.P. 
 EuclidSR Partners, L.P. 

 New Investors 

 
 Ferguson/Egan Family Trust dated 6/28/99

 Fidelity Contrafund: Fidelity Contrafund 
 Fidelity Contrafund: Fidelity Advisor New Insights Fund 
 Fred St. Goar 

Fredrick Stern 
 Gary R. Bang 

General Electric Capital Corporation 

George S. Taylor 
 Glaxo Group Limited

 Health Care Administration Company 

Heath Lukatch 
 Henry P. Massey, Jr.,
Trustee of the Massey Family Trust udt dated July 6, 1988 
 Herbert L. Heyneker 

In-Q-Tel, Inc. 
 InterWest Investors VII, L.P.

 InterWest Partners VII, L.P. 
 Invus,
L.P. 
 J.F. Shea Co., Inc., a Nominee 1999-114 
 Jacaranda Partners 
 James H. Eberwine PhD 

James W. Larrick, M.D. 
 John E.
Stobeck, PhD, M.D. 
 John M. Harland 
 Jonathan S. Hoot and Andrea T. Hoot, Trustees of the Hoot Family Revocable Trust dtd 3/16/99 
 Kenneth A. Clark 
 Kiley Revocable Trust 

Leerink Swann Co-Investment Fund, LLC 
 Leerink
Swann Holdings, LLC 
 Lehman Brothers Healthcare Venture Capital, L.P. 
 Lehman Brothers Offshore Partnership Account 2000/2001, L.P. 
 Lehman Brothers P.A., LLC

 New Investors 

 
 Lehman Brothers Partnership Account 2000/2001, L.P.

 Leo J. Parry, Jr. and Roberta J. Parry, TTEES Parry Family Revocable Trust dtd 01/22/97 

Lilly BioVentures, Eli Lilly & Company 

Markwell Partners 
 Matthew Frank 

Michael McKay 
 Michael J. Reardon Trust
Agreement dated June 5, 1996 
 Newman Family Investment Partnership 
 NR07, LLC 
 Oculus Pharmaceuticals, Inc. 
 Pat and Betsy Collins Revocable Trust 
 Patrick Tenney 

Paul Machle 
 Pauline Van Ysendoorn 

Peter B. Dervan 
 Peter S. Heinecke

 Rhett E. Brown 
 Robert D.
Mcculloch and Kathleen M. Mcculloch, Trustee or their successor(s) of the Robert D. Mcculloch and Kathleen M. Mcculloch Family Trust dated November 19, 1997 
 Robert F. Kornegay, Jr. Revocable Trust u/d/t dated May 27, 2004, Robert F. Kornegay, Jr. Trustee 
 Sightline Healthcare Fund III, L.P. 
 SMALLCAP World Fund, Inc. 

GlaxoSmithKline LLC 
 Stanley D. Hayden, and
his successor(s), as the Trustee of the Stanley D. Hayden Family Trust 
 Stephen J. Weiss 

Stephen J. Weiss and Ursula G. Weiss, Trustees of the Weiss Family 1996 Trust 
 Stephen L. Parry 
 Technogen Liquidating Trust 

The Condon Family Trust 
 The V Foundation for
Cancer Research 
 Thomas J. Parry 

  

	
	 New Investors

	
	Timothy P. Lynch
	
	TTC Fund I, LLC
	
	Variable Insurance Products Fund II: Contrafund Portfolio
	
	Versant Affiliates Fund 1-A, L.P.
	
	Versant Affiliates Fund 1-B, L.P.
	
	Versant Side Fund I, L.P.
	
	Versant Venture Capital I, L.P.
	
	Wasatch Funds, Inc.
	
	William L. Caton III, M.D.
	
	William S. Brown and Barbara G. Brown, or their successors, as trustees of The Brown FRT dtd 3/10/99
	
	WS Investment Company, LLC (2009C)
	
	WS Investment Company, LLC (2009A)

 EXHIBIT B 

SCHEDULE OF FOUNDERS 
  

	
	 Gajus V. Worthington
 c/o Fluidigm Corporation
 7000 Shoreline Court, Suite 100

South San Francisco, CA 94080

	
	 Stephen R. Quake
 636 Alvarado Row
 Stanford, CA , 94305

 EXHIBIT C 

PRIOR INVESTORS 
  

	
	 Certain Warrantholders

	
	In-Q-Tel Employee Fund, LLC
	
	In-Q-Tel, Inc.
	
	Lighthouse Capital Partners V, L.P.
	
	 Prior Series E Investors

	
	Alfred J. Mandel
	
	AllianceBernstein Venture Fund I, L.P.
	
	Alloy Partners 2002, L.P.
	
	Alloy Ventures 2002, L.P.
	
	Alloy Ventures 2005, L.P.
	
	Biomedical Sciences Investment Fund Pte Ltd
	
	Bruce Burrows
	
	Bruce Burrows
	
	Clearmoon & Co.
	
	Clipperbay & Co.
	
	EuclidSR Biotechnology Partners, L.P.
	
	EuclidSR Partners, L.P.
	
	Ferguson/Egan Family Trust Dated 6/28/99
	
	Fredrick H. Stern
	
	Health Care Administration Company
	
	In-Q-Tel Employee Fund, LLC
	
	In-Q-Tel, Inc.
	
	Interwest Investors VII, L.P.
	
	Interwest Partners VII, L.P.
	
	John M. Harland
	
	Leerink Swann Co-Investment Fund, LLC
	
	Leerink Swann Holdings, LLC
	
	Lehman Brothers Healthcare Venture Capital L.P.
	
	Lehman Brothers Offshore Partnership Account 2000/2001, L.P.

  

	
	 Prior Series E Investors

	
	Lehman Brothers P.A. LLC
	
	Lehman Brothers Partnership Account 2000/2001, L.P.
	
	Lilly Bio Ventures, Eli Lilly and Company
	
	Fidelity Contrafund-Fidelity Advisor New Insights Fund
	
	Fidelity Contrafund-Fidelity Contrafund
	
	Variable Insurance Products Fund II-Contrafund Portfolio
	
	PACO c/o 80-16-200-1037662
	
	PACO c/o 80-16-200-1037670
	
	Pauline E. van Ysendoorn
	
	Rhett E. Brown
	
	SightLine Healthcare Fund III, L.P.
	
	The Condon Family Trust
	
	The V Foundation for Cancer Research
	
	Versant Affiliates Fund 1-A, L.P.
	
	Versant Affiliates Fund 1-B, L.P.
	
	Versant Side Fund I, L.P.
	
	Versant Venture Capital I, L.P.
	
	 Prior Series D Investors

	
	Alejandro Berenstein, MD
	
	Allan Johnston
	
	Alloy Partners 2002, L.P.
	
	Alloy Ventures 2005, L.P.
	
	Beveren Company
	
	Biomedical Sciences Investment Fund Pte Ltd
	
	Bradford W. Baer
	
	Bruce Burrows
	
	Clark-Boyd Family Trust
	
	David S. Frampton and Gaja Roberta Frampton, as Trustees of the Frampton Family Trust u/a/d 4/25/03
	
	Edward R. LeMoure
	
	Erik Vanderburg
	
	EuclidSR Biotechnology Partners, L.P.
	
	EuclidSR Partners, L.P.

  

	
	 Prior Series D Investors

	
	Ferguson/Egan Family Trust
	
	Frances Hamilton Arnold
	
	Frederick Stern
	
	Gary R. Bang
	
	GE Capital Equity Investments, Inc.
	
	Health Care Administration Company
	
	Henry P. Massey, Jr., Trustee of The Massey Family Trust UDT Dated July 6, 1988
	
	Howard R. Engelson and Miriam T. Engelson Trustees of the Engelson Family Trust U/A DTD 05/26/1994
	
	Interwest Investors VII, L.P.
	
	Interwest Partners VII, L.P.
	
	Invus, L.P.
	
	J.F. Shea Co., Inc., as Nominee 1999-114
	
	John M. Harland
	
	Kiley Revocable Trust
	
	Lehman Brothers Healthcare Venture Capital, L.P.
	
	Lehman Brothers Offshore Partnership Account 2000/2001, L.P.
	
	Lehman Brothers P.A. LLC
	
	Lehman Brothers Partnership Account 2000/2001, L.P.
	
	Lilly BioVentures, Eli Lilly and Company
	
	Markwell Partners
	
	Pat and Betsy Collins Revocable Trust
	
	Patrick Tenney
	
	Paul Machle
	
	Piper Jaffray Healthcare Fund III, L.P.
	
	Robert D. McCulloch and Kathleen M. McCulloch, Trustee, or their successor(s) of THE ROBERT D. McCULLOCH AND KATHLEEN M. McCULLOCH FAMILY TRUST AGREEMENT, DATED NOVEMBER 19,
1997
	
	Robert F. Kornegay, Jr., Trustee of the Robert Kornegay Trust U/A DTD May 27, 2004
	
	Stanley D. Hayden
	
	The V Foundation for Cancer Research
	
	Versant Affiliates Fund 1-A, L.P.
	
	Versant Affiliates Fund 1-B, L.P.
	
	Versant Side Fund I, L.P.

  

	
	 Prior Series D Investors

	
	Versant Venture Capital I, L.P.
	
	 Prior Series C Investors

	
	Alfred J. Mandel
	
	Allan Johnston
	
	Beveren Company
	
	Bradford W. Baer
	
	Bruce Burrows
	
	Burwen Family Trust U/D/T dated 9/30/88
	
	Charles R. Engles
	
	David Frampton, Trustee of 2000 David Scott Frampton Trust
	
	Erik T. Engelson, Trustee of the Elizabeth North Kuechler Engelson Trust UDT dated January 17, 2001
	
	Erik T. Engelson, Trustee of the Eric T. Engelson Trust UDT dated March 29, 2000
	
	EuclidSR Biotechnology Partners, L.P.
	
	EuclidSR Partners, L.P.
	
	Frances Arnold
	
	GE Capital Equity Investments, Inc.
	
	George S. Taylor
	
	Glaxo Group Limited
	
	Health Care Administrative Co.
	
	Heath Lukatch
	
	Henry P. Massey, Jr., Trustee, The Massey Family Trust U/A DTD 7/06/88
	
	Herbert L. Heyneker
	
	Howard R. Engelson
	
	Interwest Investors VII, L.P.
	
	Interwest Partners VII, L.P.
	
	James W. Larrick
	
	John E. Strobeck, MD PhD
	
	Kenneth A. Clark
	
	Kiley Revocable Trust
	
	Lehman Brothers Healthcare Venture Capital L.P.
	
	Lehman Brothers Offshore Partnership Account 2000/2001, L.P.
	
	Lehman Brothers P.A. LLC

  

	
	 Prior Series C Investors

	
	Lehman Brothers Partnership Account 2000/2001, L.P.
	
	Leo J. Parry and Roberta J. Parry TTEES Parry Family Revocable Trust DTD 1/22/97
	
	Lilly BioVentures, Eli Lilly and Company
	
	Markwell Partners
	
	Michael H. McKay
	
	Michael J. Reardon
	
	Paul Machle
	
	Peter S. Heinecke
	
	Piper Jaffray Healthcare Fund III, L.P.
	
	Security Trust Co., Custodian FBO Frank Ruderman IRA/RO
	
	Singapore Bio-Innovations Pte Ltd
	
	SmithKline Beecham Corporation
	
	Stephen J. Weiss
	
	Stephen L. Parry
	
	TBCC Funding Trust II
	
	The Condon Family Trust Dated 4/5/90
	
	The Hoot Family Revocable Trust
	
	Thomas J. Parry
	
	Timothy P. Lynch
	
	Versant Affiliates Fund 1-A, L.P.
	
	Versant Affiliates Fund 1-B, L.P.
	
	Versant Side Fund I, L.P.
	
	Versant Venture Capital I, L.P.
	
	William S. Brown and Barbara G. Brown, or their successors, as Trustees of the Brown Family Revocable Trust dated March 10, 1999
	
	WS Investment Company, LLC (2001D)
	
	 Prior Series A and Series B Investors

	
	Versant Venture Capital I, L.P.
	
	Versant Side Fund I, L.P.
	
	Versant Affiliates Fund 1-A, L.P.
	
	Versant Affiliates Fund 1-B, L.P.
	
	Interwest Partners VII, L.P.

  

	
	 Prior Series A and Series B Investors

	
	Interwest Investors VII, L.P.
	
	Technogen Associates, L.P.
	
	Frances Arnold
	
	Pat and Betsy Collins Revocable Trust
	
	The 2000 David Scott Frampton Trust
	
	Stanley D. Hayden
	
	TTC Fund I, LLC
	
	Traff Family 1993 Irrevocable Trust
	
	Stephen J. Weiss and Ursula G. Weiss, Trustees of the Weiss Family 1996 Trust
	
	WS Investment Company 2000B
	
	Bradford W. Baer
	
	Thomas L. Barton
	
	Beveren Company
	
	Burwen Family Trust U/D/T dated 9/30/88
	
	Bruce Burrows
	
	Matthew Collier
	
	Peter B. Dervan
	
	John East
	
	Pamela M. East
	
	James H. Eberwine
	
	Charles R. Engles
	
	Ferguson/Egan Family Trust Dated 6/28/99
	
	Matthew Frank
	
	Bradford S. Goodwin and Cathy W. Goodwin, as Trustees of the Goodwin Family Trust U/A/D 7/30/97
	
	Dwayne Hardy
	
	John M. Harland
	
	Health Care Administration Company
	
	The Heckmann Family Trust / Desert Springs Investment
	
	Peter S. Heinecke
	
	Jonathan S. Hoot and Andrea T. Hoot, Trustees of the 1999 Hoot Family Revocable Trust DTD 3/16/99
	
	Joseph M. Jacobsen
	
	Kiley Revocable Trust
	
	James W. Larrick, M.D. Ph.D

  

	
	 Prior Series A and Series B Investors

	
	Markwell Partners
	
	Henry P. Massey, Jr., TTEE Massey Family Trust U/A DTD 7/06/88
	
	Allan May, Trustee, Intervivos Trust Dated 5/14/91
	
	Charles C. Moore
	
	Newman Family Investment Partnership
	
	Fredrick Stern
	
	Fred St. Goar
	
	George S. Taylor
	
	Traff Family 1993 Irrevocable Trust / Desert Springs Investment
	
	WS Investment Company 99B
	
	William L. Caton III M.D.
	
	Pat and Betsy Collins Revocable Trust
	
	The Condon Family Trust
	
	Stanley D. Hayden
	
	Jacaranda Partners
	
	J.F. Shea Co., Inc. as Nominee 1999-114

 FLUIDIGM CORPORATION 

AMENDMENT NO. 1 
 TO NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This Amendment
No. 1 (this “Amendment”) to that certain Ninth Amended and Restated Investor Rights Agreement, dated as of November 16, 2009 (the “Rights Agreement”), by and among Fluidigm Corporation, a Delaware
corporation (the “Company”), and the Investors and Founders named therein is entered into effective as of June 14, 2010, by and among the Company and the undersigned Investors constituting the Holders of at least two-thirds ( 2/3) of the outstanding shares of the Registrable
Securities now held by all Holders (assuming the exercise or conversion of all outstanding Eligible Securities). Capitalized terms not defined herein have the meanings set forth in the Rights Agreement. 

RECITALS 

WHEREAS, on June 14, 2010, the Company and Lighthouse Capital Partners V, L.P. (“Lighthouse”) entered into
that certain Amendment No. 8 (the “Lighthouse Amendment”) to Loan and Security Agreement No. 4561, dated as of March 29, 2005, as amended; 
 WHEREAS, under the terms of the Lighthouse Amendment, the Company agreed to amend and restate certain warrants to purchase preferred stock that the Company previously issued to Lighthouse (the
“Restated Warrants”) to provide that such Restated Warrants are exercisable for the right to purchase shares of a newly created series of the Company’s preferred stock (the “Restated Warrant Shares”);

 WHEREAS, under the terms of the Lighthouse Amendment, the Company agreed to issue to Lighthouse a new warrant to purchase
preferred stock (the “Additional Warrant”) exercisable for the right to purchase up to that number of shares of the Company’s Preferred Stock (as defined in the Additional Warrant) equal to $699,760 divided by the Purchase
Price (as defined in the Additional Warrant) (the “Additional Warrant Shares”); 
 WHEREAS, under the terms of
the Restated Warrants and the Additional Warrant, the Company agreed to grant to Lighthouse the rights of a “Holder” and “Warrantholder” under the Rights Agreement, including the registration rights contained therein, with
respect to the Restated Warrant Shares and the Additional Warrant Shares; 
 WHEREAS, the Company and the undersigned Investors
desire to amend the Rights Agreement to grant to Lighthouse the rights of a “Holder” and “Warrantholder” under the Rights Agreement and provide for registration rights with respect to the Restated Warrant Shares and the
Additional Warrant Shares; 
 WHEREAS, the Company and the undersigned Investors desire to amend the definition of “Warrant
Shares” under the Rights Agreement to delete language that refers to certain warrants to purchase shares of the Company’s preferred stock that are no longer outstanding; 

 WHEREAS, pursuant to Section 6.7 of the Rights Agreement, the Rights Agreement may be
amended with the written consent of the Company and Holders of at least two-thirds ( 2/3) of the outstanding shares of the Registrable Securities then held by Holders (assuming the exercise or conversion of all outstanding Eligible Securities) (the “Requisite Holders”); and

 WHEREAS, the Company and the undersigned Investors constituting the Requisite Holders desire to amend the Rights
Agreement to provide for the foregoing changes. 
 NOW, THEREFORE, in consideration of the foregoing, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually agree as follows: 
 AGREEMENT 
 SECTION 7 Amendment and Restatement of Definition.
The definition of “Lighthouse Preferred Warrants” set forth in Section 1.1 is hereby amended and restated in its entirety as follows: 
 ““Lighthouse Preferred Warrants” shall mean (i) the Amended and Restated Preferred Stock Purchase Warrant dated June 14, 2010, pursuant to which Lighthouse Capital
Partners V, L.P. (“Lighthouse”) may purchase shares of the Company’s authorized Series D-1 Preferred Stock; (ii) the Amended and Restated Preferred Stock Purchase Warrant dated June 14, 2010, pursuant to which
Lighthouse may purchase shares of the Company’s authorized Series E-1 Preferred Stock; (iii) the Amended and Restated Preferred Stock Purchase Warrant dated June 14, 2010, pursuant to which Lighthouse may purchase shares of the
Company’s authorized Series E-1 Preferred Stock; and (iv) the Preferred Stock Purchase Warrant dated June 14, 2010, pursuant to which Lighthouse may purchase shares of the Company’s authorized Preferred Stock.”

 SECTION 8 Amendment and Restatement of Definition. The definition of “Warrant Shares” set forth in
Section 1.1 is hereby amended and restated in its entirety as follows: 
 ““Warrant Shares” shall
mean the shares of Common Stock of the Company issued or issuable upon conversion of the (i) Series C Preferred Stock issued or issuable upon exercise or conversion of (A) the warrant to purchase up to 17,500 shares of Series C Preferred
Stock issued to TBCC Funding Trust II (“TBCC”) pursuant to the Master Loan and Security Agreement dated March 27, 2002 by and between the Company and Transamerica Technology Finance Corporation; and (B) the warrant to
purchase up to 31,008 shares of Series C Preferred Stock issued to General Electric Capital Corporation (“GE Capital”) in connection with the Master Security Agreement dated as of November 8, 2002, as amended (the
“Master Security Agreement”) by and between the Company and GE Capital; (ii) the Series D Preferred Stock issued or issuable upon exercise or conversion of (A) the warrant to purchase up to 37,500 shares of Series D
Preferred Stock dated March 18, 2004 and issued to GE 

  
 -2-

 
Capital in connection with extensions of credit to the Company; and (B) the Lighthouse Preferred Warrants; (iii) the Series D-1 Preferred Stock issued or issuable upon exercise or
conversion of the Lighthouse Preferred Warrants; (iv) the Series E Preferred Stock issued or issuable upon exercise or conversion of the warrants to purchase shares of Preferred Stock of the Company issued to certain Investors under the
Note and Warrant Purchase Agreement dated as of August 25, 2009; and (v) the Series E-1 Preferred Stock issued or issuable upon exercise or conversion of the Lighthouse Preferred Warrants. TBCC, GE Capital, and Lighthouse are collectively
referred to herein as “Warrantholders.”” 
 SECTION 9 Governing Law. This Amendment shall be
construed in accordance with, and governed in all respects by, the laws of the State of California, as applied to agreements entered into, and to be performed entirely in such state, between residents of such state. 

SECTION 10 Rights Agreement. Wherever necessary, all other terms of the Rights Agreement are hereby amended to be consistent
with the terms of this Amendment. Except as specifically set forth herein, the Rights Agreement shall remain in full force and effect 
 SECTION 11 Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of
which together shall constitute one instrument. 
 * * * 

  
 -3-

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	COMPANY:	 	FLUIDIGM CORPORATION
			
		 	By:	 	 /s/ Gajus V. Worthington

		 		 	Gajus V. Worthington,
		 		 	President and Chief Executive Officer

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 ABT HOLDING COMPANY
 (FORMERLY KNOWN AS ATHERSYS, INC.)

			
		 	By:	 	 /s/ Laura Campbell

			
		 	Name:	 	 Laura Campbell

			
		 	Title:	 	 VP - Finance

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	ALLOY VENTURES 2005, L.P.
			
		 	By:	 	Alloy Ventures 2005, LLC
		 		 	its General Partner
			
		 	By:	 	/s/ [Illegible]                          
                  
			
		 	Name:	 	                             
                                   
			
		 	Title:	 	Managing Member of Alloy Ventures 2005 LLC
		 		 	Managing Member of Alloy Ventures 2005, L.P.
		
		 	ALLOY VENTURES 2002, L.P.
		 	ALLOY PARTNERS 2002, L.P.
			
		 	By:	 	Alloy Ventures 2002, LLC
		 		 	its General Partner
			
		 	By:	 	/s/ [Illegible]                          
                  
			
		 	Name:	 	                             
                                   
			
		 	Title:	 	Managing Member of Alloy Ventures 2002 LLC
		 		 	Managing Member of Alloy Partners 2002, L.P.
		 		 	and Alloy Ventures 2002, L.P.                     
       

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 BIOMEDICAL SCIENCES INVESTMENT FUND

PTE LTD

			
		 	By:	 	 /s/ Chu Swee Yeok

			
		 	Name:	 	 Chu Swee Yeok

			
		 	Title:	 	 Director

		
		 	SINGAPORE BIO-INNOVATIONS PTE LTD
			
		 	By:	 	 /s/ Eugene Khoo Kay Jin

			
		 	Name:	 	 Eugene Khoo Kay Jin

			
		 	Title:	 	 Director

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 VERSANT AFFILIATES FUND 1-A, L.P.

VERSANT AFFILIATES FUND 1-B, L.P.
 VERSANT SIDE FUND I, L.P.

VERSANT VENTURE CAPITAL I, L.P.

			
		 	By:	 	 Versant Ventures I, LLC
 its
General Partner

			
		 	By:	 	 /s/ Samuel D. Colella

			
		 	Name:	 	 Samuel D. Colella

			
		 	Title:	 	 Managing Director

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 LEHMAN BROTHERS HEALTHCARE VENTURE

CAPITAL L.P.

			
		 	By:	 	 Lehman Brothers HealthCare Venture
 Capital Associates L.P.,
 its General Partner

			
		 	By:	 	 LB I Group Inc.,
 its
General Partner

			
		 	By:	 	 /s/ Ashvin Rao

			
		 	Name:	 	 Ashvin Rao

			
		 	Title:	 	 Vice President

		
		 	LEHMAN BROTHERS P.A. LLC
			
		 	By:	 	 /s/ Ashvin Rao

			
		 	Name:	 	 Ashvin Rao

			
		 	Title:	 	 Vice President

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 LEHMAN BROTHERS PARTNERSHIP ACCOUNT

2000/2001, L.P.

			
		 	By:	 	 LB I Group Inc.,
 its
General Partner

			
		 	By:	 	 /s/ Ashvin Rao

			
		 	Name:	 	 Ashvin Rao

			
		 	Title:	 	 Vice President

		
		 	 LEHMAN BROTHERS OFFSHORE PARTNERSHIP

ACCOUNT 2000/2001, L.P.

			
		 	By:	 	 LB I Offshore Partners Group Ltd.,
 its General Partner

			
		 	By:	 	 /s/ Ashvin Rao

			
		 	Name:	 	 Ashvin Rao

			
		 	Title:	 	 Vice President

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	EUCLIDSR PARTNERS, L.P.
			
		 	By:	 	 EuclidSR Associates, L.P.,

its General Partner

			
		 	By:	 	 /s/ Raymond J. Whitaker

			
		 	Name:	 	 Raymond J. Whitaker

			
		 	Title:	 	 General Partner

		
		 	EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.
			
		 	By:	 	 EuclidSR Biotechnology Associates, L.P.,
 its General Partner

			
		 	By:	 	 /s/ Raymond J. Whitaker

			
		 	Name:	 	 Raymond J. Whitaker

			
		 	Title:	 	 General Partner

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	INTERWEST PARTNERS VII, L.P.
			
		 	By:	 	 InterWest Management Partners VII, LLC,
 its General Partner

			
		 	By:	 	 /s/ W. Stephen Holmes

			
		 	Name:	 	 W. Stephen Holmes

			
		 	Title:	 	 Managing Director

		
		 	INTERWEST INVESTORS VII, L.P.
			
		 	By:	 	 InterWest Management Partners VII, LLC,
 its General Partner

			
		 	By:	 	 /s/ W. Stephen Holmes

			
		 	Name:	 	 W. Stephen Holmes

			
		 	Title:	 	 Managing Director

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

											
	INVESTORS:	 		 		 		 		 	
	 	 	 	 	SMALLCAP WORLD FUND, INC.	 	 	 	 
				
		 		 	By:	 	Capital Research and Management
		 		 		 	Company, its investment adviser	 		 	
						
		 		 	By:	 	 /s/ Michael J. Downer
	 		 	
						
		 		 	Name:	 	 Michael J. Downer
	 		 	
						
		 		 	Title:	 	 Senior Vice President and Secretary
	 		 	

  

											
		 		 	Approved for Signature	 	 	 		 	
		 		 		 	WRB	 		 	
		 		 	by CRMC Legal Dept.	 	 	 		 	

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 FIDELITY CONTRAFUND:
 FIDELITY ADVISOR NEW INSIGHTS FUND

			
		 	By:	 	 /s/ Jeffrey Christian

			
		 	Name:	 	 Jeffrey Christian

			
		 	Title:	 	 Deputy Treasurer

		
		 	 FIDELITY CONTRAFUND: FIDELITY

CONTRAFUND

			
		 	By:	 	 /s/ Jeffrey Christian

			
		 	Name:	 	 Jeffrey Christian

			
		 	Title:	 	 Deputy Treasurer

		
		 	 VARIABLE INSURANCE PRODUCTS FUND II:

CONTRAFUND PORTFOLIO

			
		 	By:	 	 /s/ Jeffrey Christian

			
		 	Name:	 	 Jeffrey Christian

			
		 	Title:	 	 Deputy Treasurer

  

[Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	LEERINK SWANN HOLDINGS, LLC	 	
				
		 	By:	 	 /s/ Joseph R. Gentile
	 	
				
		 	Name:	 	 Joseph R. Gentile
	 	
				
		 	Title:	 	 CAO, CFO
	 	
		
		 	LEERINK SWANN CO-INVESTMENT FUND, LLC
				
		 	By:	 	 /s/ Joseph R. Gentile
	 	
				
		 	Name:	 	 Joseph R. Gentile
	 	
				
		 	Title:	 	 CAO, CFO
	 	

  
 [Amendment
No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	CROSS CREEK CAPITAL, L.P.	 	
				
		 	By:	 	Cross Creek Capital GP, L.P.,	 	
		 		 	its Sole General Partner	 	
				
		 	By:	 	Cross Creek Capital, LLC,	 	
		 		 	its Sole General Partner	 	
				
		 	By:	 	Wasatch Advisors, Inc.,	 	
		 		 	its Sole Member	 	
				
		 	By:	 	 /s/ Daniel Thurber
	 	
				
		 	Name:	 	 Daniel Thurber
	 	
				
		 	Title:	 	 Vice President
	 	

  
 [Amendment
No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	CROSS CREEK CAPITAL EMPLOYEES’ FUND, 
L.P.
				
		 	By:	 	Cross Creek Capital GP, L.P.,	 	
		 		 	its Sole General Partner	 	
				
		 	By:	 	Cross Creek Capital, LLC,	 	
		 		 	its Sole General Partner	 	
				
		 	By:	 	Wasatch Advisors, Inc.,	 	
		 		 	its Sole Member	 	
				
		 	By:	 	 /s/ Daniel Thurber
	 	
				
		 	Name:	 	 Daniel Thurber
	 	
				
		 	Title:	 	 Vice President
	 	

  
 [Amendment
No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	WASATCH FUNDS, INC.	 	
		 	Wasatch Small Cap Growth Fund	 	
				
		 	By:	 	Wasatch Advisors, Inc.,	 	
		 		 	its Investment Adviser	 	
				
		 	By:	 	 /s/ Daniel Thurber
	 	
				
		 	Name:	 	 Daniel Thurber
	 	
				
		 	Title:	 	 Vice President
	 	

  
 [Amendment
No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	SIGHTLINE HEALTHCARE FUND III, L.P.	 	
				
		 	By:	 	 /s/ Maureen Harder
	 	
				
		 	Name:	 	 Maureen Harder
	 	
				
		 	Title:	 	 Managing Director
	 	

  
 [Amendment
No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	OCULUS PHARMACEUTICALS, INC.	 	
				
		 	By:	 	 /s/ William Lehmann
	 	
				
		 	Name:	 	 William (BJ) Lehmann
	 	
				
		 	Title:	 	 President
	 	

  
 [Amendment
No. 1 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 FLUIDIGM CORPORATION 

AMENDMENT NO. 2 
 TO NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This Amendment
No. 2 (this “Amendment”) to that certain Ninth Amended and Restated Investor Rights Agreement, dated as of November 16, 2009 (the “Rights Agreement”) and as amended on June 2, 2010, by and among
Fluidigm Corporation, a Delaware corporation (the “Company”), and the Investors and Founders named therein is entered into effective as of August 16, 2010, by and among the Company and the undersigned Investors constituting the
Holders of at least two-thirds ( 2/3) of the
outstanding shares of the Registrable Securities now held by all Holders (assuming the exercise or conversion of all outstanding Eligible Securities). Capitalized terms not defined herein have the meanings set forth in the Rights Agreement.

 RECITALS 
 WHEREAS, on July 8, 2010, the Company extended an offer to all holders of warrants to acquire the Company’s preferred stock with an exercise price in excess of $7.00 per share (each an
“Eligible Warrant” and together, the “Eligible Warrants”), the opportunity to amend their respective Eligible Warrants to provide that (i) the exercise price of such amended Eligible Warrants (the
“Amended Eligible Warrant”) will be $7.00 per share and (ii) such Amended Eligible Warrants will be exercisable for (a) a number of shares of an alternative series of the Company’s preferred stock (the “Shadow
Preferred Stock”) equal to the number of shares of Company’s preferred stock currently issuable upon exercise of the Eligible Warrant and (b) an equivalent number of shares of the Company’s common stock, subject to such
holder’s agreement to exercise the Amended Eligible Warrant immediately in full and for cash (the “Offer”); 
 WHEREAS, the series of Shadow Preferred Stock to be issued upon exercise of the Amended Eligible Warrants pursuant to the Offer shall be comprised of Series C-1 preferred stock, Series D-1 preferred Stock
and Series E-1 preferred stock; 
 WHEREAS, the Company and the undersigned stockholders desire that the holders of Series C-1
preferred stock, Series D-1 preferred stock and Series E-1 preferred stock issued upon exercise of the Amended Eligible Warrants shall have the same rights as Holders (as defined in the Rights Agreements), including registration rights, as the
Company’s other preferred stock set forth in the Rights Agreement; 
 WHEREAS, pursuant to Section 6.7 of the Rights
Agreement, the Rights Agreement may be amended with the written consent of the Company and Holders of at least two-thirds
( 2/3) of the outstanding shares of the Registrable
Securities then held by Holders (assuming the exercise or conversion of all outstanding Eligible Securities) (the “Requisite Holders”); and 
 WHEREAS, the Company and the undersigned Investors constituting the Requisite Holders desire to amend the Rights Agreement to provide for the foregoing changes. 

 NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually agree as follows: 

AGREEMENT 

SECTION 12 Addition of New Definitions in Section 1.1. The following new definitions are hereby added to Section 1.1:

 ““Amended Eligible Warrant(s)” shall mean those Eligible Warrants modified pursuant to and in
accordance with the Offer.” 
 ““Eligible Warrant(s)” shall mean those warrants to acquire the
Company’s preferred stock with an exercise price in excess of $7.00 per share.” 
 ““Offer”
shall mean that certain offer extended on or about July 8, 2010 to all holders of Eligible Warrants, the opportunity to amend their respective Eligible Warrants to provide that (i) the exercise price of the Amended Eligible Warrants will
be $7.00 per share and (ii) the Amended Eligible Warrants will be exercisable for (a) a number of shares of Shadow Preferred Stock equal to the number of shares of Company’s preferred stock currently issuable upon exercise of the
Eligible Warrant and (b) an equivalent number of shares of the Company’s common stock, subject to such holder’s agreement to exercise the Amended Eligible Warrant immediately in full and for cash.” 

““Shadow Preferred Stock” shall mean that certain series of the Company’s preferred stock having the same
rights, preferences and privileges as the original series of preferred stock issuable upon exercise of the Eligible Warrant, except that the original issuance price and liquidation preference of such series of preferred stock shall be $7.00. Such
Shadow Preferred Stock shall consist of “Series C-1 Preferred Stock,” “Series D-1 Preferred Stock” and “Series E-1 Preferred Stock,” as applicable. 

SECTION 13 Amendment and Restatement of Definition. The definition of “Eligible Securities” set forth in
Section 1.1 is hereby amended and restated in its entirety as follows: 
 ““Eligible Securities”
shall mean (i) the Series A Preferred Stock issued pursuant to the Series A Preferred Stock Purchase Agreement dated December 1, 1999; (ii) the Series B Preferred Stock issued pursuant to the Series B Preferred
Stock Purchase Agreement dated July 5, 2000; (iii) the Series C Preferred Stock issued pursuant to the Series C Preferred Stock Purchase Agreement dated October 23, 2001; (iv) the Series C Preferred Stock issued
pursuant to the Series C Preferred Stock Purchase Agreement dated November 1, 2002; (v) the Series C Preferred Stock issued pursuant to the Series C Preferred Stock and Warrant Purchase Agreement dated

  
 -2-

 
September 22, 2003; (vi) the Series D Preferred Stock issued pursuant to the Series D Preferred Stock Purchase Agreement dated December 18, 2003; (vii) the Series D Preferred
Stock issued pursuant to the Series D Preferred Stock Purchase Agreement dated August 16, 2005; (viii) the Series D Preferred Stock issued upon conversion of convertible promissory note(s) issued pursuant to the Convertible Promissory
Note Purchase Agreement (the “CNPA”) dated December 18, 2003, as amended by Amendment No. 1 to Convertible Note Purchase Agreement dated December 17, 2004, between the Company and Biomedical Sciences Investment Fund
Pte Ltd (the “BMSIF”); (ix) the Series D Preferred Stock issued upon conversion of convertible promissory note(s) issued in connection with the Convertible Note Agreement (the “CNA”) dated December 18,
2003, between the Company and Invus, L.P. (the “Invus”); (x) the Series E Preferred Stock issued pursuant to the Series E Preferred Stock Purchase Agreement dated June 13, 2006, as amended (the “Prior Purchase
Agreement”); (xi); the Series E Preferred Stock issued pursuant to the 2009 Purchase Agreement; (xii) the Series C-1 Preferred Stock, the Series D-1 Preferred Stock and the Series E-1 Preferred Stock issued upon exercise of the
Amended Eligible Warrants, as applicable, pursuant to and in accordance with the Offer; (xiii) all Securities acquired by any Investor pursuant to the rights of first offer described in Sections 3 or 4 of this Agreement; and (xiv) any
Securities issued with respect to the foregoing upon any stock split, stock dividend, recapitalization, or similar event or upon any exercise or conversion, as applicable.” 

SECTION 14 Governing Law. This Amendment shall be construed in accordance with, and governed in all respects by, the laws of the
State of California, as applied to agreements entered into, and to be performed entirely in such state, between residents of such state. 
 SECTION 15 Rights Agreement. Wherever necessary, all other terms of the Rights Agreement are hereby amended to be consistent with the terms of this Amendment. Except as specifically set forth
herein, the Rights Agreement shall remain in full force and effect 
 SECTION 16 Counterparts. This Amendment may be
executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

* * * 

  
 -3-

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	COMPANY:	 	FLUIDIGM CORPORATION	 	
				
		 	By:	 	 /s/ Gajus V. Worthington
	 	
		 		 	Gajus V. Worthington,	 	
		 		 	President and Chief Executive Officer	 	

  
 [Amendment
No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	ALLOY VENTURES 2005, L.P.
			
		 	By:	 	Alloy Ventures 2005, LLC
		 		 	its General Partner
			
		 	By:	 	/s/ [Illegible]                          
                  
			
		 	Name:	 	                             
                                   
			
		 	Title:	 	Managing Member of Alloy Ventures 2005 LLC
		 		 	Managing Member of Alloy Ventures 2005, L.P.
		
		 	ALLOY VENTURES 2002, L.P.
		 	ALLOY PARTNERS 2002, L.P.
			
		 	By:	 	Alloy Ventures 2002, LLC
		 		 	its General Partner
			
		 	By:	 	/s/ [Illegible]                          
                  
			
		 	Name:	 	                             
                                   
			
		 	Title:	 	Managing Member of Alloy Ventures 2002 LLC
		 		 	Managing Member of Alloy Partners 2002, L.P.
		 		 	and Alloy Ventures 2002, L.P.                     
       

  
 [Amendment
No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

							
	INVESTORS:	 	SIGHTLINE HEALTHCARE FUND III, L.P.	 	
				
		 	By:	 	 /s/ Buzz Benson
	 	
				
		 	Name:	 	 Buzz Benson
	 	
				
		 	Title:	 	 Managing Director
	 	

  
 [Amendment
No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	INTERWEST PARTNERS VII, L.P.
			
		 	By:	 	InterWest Management Partners VII, LLC,
		 		 	its General Partner
			
		 	By:	 	 /s/ Michael Sweeney

			
		 	Name:	 	 Michael Sweeney

			
		 	Title:	 	 As agent for the general partner

		
		 	INTERWEST INVESTORS VII, L.P.
			
		 	By:	 	InterWest Management Partners VII, LLC,
		 		 	its General Partner
			
		 	By:	 	 /s/ Michael Sweeney

			
		 	Name:	 	 Michael Sweeney

			
		 	Title:	 	 As agent for the general partner

[Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	FIDELITY CONTRAFUND:
		 	FIDELITY ADVISOR NEW INSIGHTS FUND
			
		 	By:	 	 /s/ Jeffrey Christian

			
		 	Name:	 	 Jeffrey Christian

			
		 	Title:	 	 Deputy Treasurer

		
		 	FIDELITY CONTRAFUND: FIDELITY
		 	CONTRAFUND
			
		 	By:	 	 /s/ Jeffrey Christian

			
		 	Name:	 	 Jeffrey Christian

			
		 	Title:	 	 Deputy Treasurer

		
		 	VARIABLE INSURANCE PRODUCTS FUND II:
		 	CONTRAFUND PORTFOLIO
			
		 	By:	 	  

			
		 	Name:	 	  

			
		 	Title:	 	  

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	EUCLIDSR PARTNERS, L.P.
			
		 	By:	 	EuclidSR Associates, L.P.,
		 		 	its General Partner
			
		 	By:	 	 /s/ Raymond J. Whitaker

			
		 	Name:	 	 Raymond J. Whitaker

			
		 	Title:	 	 General Partner

		
		 	EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.
			
		 	By:	 	EuclidSR Biotechnology Associates, L.P.,
		 		 	its General Partner
			
		 	By:	 	 /s/ Raymond J. Whitaker

			
		 	Name:	 	  

			
		 	Title:	 	 General Partner

[Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	LILLY BIOVENTURES, ELI LILLY & COMPANY
			
		 	By:	 	 /s/ S. Edward Torres

			
		 	Name:	 	 S. Edward Torres

			
		 	Title:	 	  

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	ALLIANCEBERNSTEIN VENTURE FUND I, L.P.
			
		 	By:	 	 AllianceBernstein ESG Venture Management,
 L.P., its general partner

			
		 	By:	 	 AllianceBernstein Global Derivatives
 Corporation, its general partner

			
		 	By:	 	 /s/ Amy Raskin

			
		 	Name:	 	 Amy Raskin

			
		 	Title:	 	 Senior Vice President

[Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	 VERSANT AFFILIATES FUND 1-A, L.P.

VERSANT AFFILIATES FUND 1-B, L.P.
 VERSANT SIDE FUND I, L.P.

VERSANT VENTURE CAPITAL I, L.P.

			
		 	By:	 	Versant Ventures I, LLC
		 		 	its General Partner
			
		 	By:	 	 /s/ Samuel D. Colella

			
		 	Name:	 	 Samuel D. Colella

			
		 	Title:	 	 Managing Director

[Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
 INVESTORS: 
  

	
	 /s/ Bruce Burrows

	BRUCE BURROWS

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	ARTEMIS HEALTH, INC.
		 	a Delaware Corporation
			
		 	By:	 	 /s/ Richard P. Rava

			
		 	Name:	 	 Richard P. Rava

			
		 	Title:	 	 President

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	CROSS CREEK CAPITAL, L.P.
			
		 	By:	 	Cross Creek Capital GP, L.P.,
		 		 	its Sole General Partner
			
		 	By:	 	Cross Creek Capital, LLC,
		 		 	its Sole General Partner
			
		 	By:	 	Wasatch Advisors, Inc.,
		 		 	its Sole Member
			
		 	By:	 	 Daniel Thurber

			
		 	Name:	 	 /s/ Daniel Thurber

			
		 	Title:	 	 VP

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	CROSS CREEK CAPITAL EMPLOYEES’ FUND, L.P.
			
		 	By:	 	 Cross Creek Capital GP, L.P.,

its Sole General Partner

			
		 	By:	 	 Cross Creek Capital, LLC,
 its
Sole General Partner

			
		 	By:	 	 Wasatch Advisors, Inc.,
 its
Sole Member

			
		 	By:	 	 /s/ Daniel Thurber

			
		 	Name:	 	 Daniel Thurber

			
		 	Title:	 	 VP

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	WASATCH FUNDS, INC.
		 	Wasatch Small Cap Growth Fund
			
		 	By:	 	 Wasatch Advisors, Inc.,
 its
Investment Adviser

			
		 	By:	 	 /s/ Daniel Thurber

			
		 	Name:	 	 Daniel Thurber

			
		 	Title:	 	 VP

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	INVESTORS:	 	BIOMEDICAL SCIENCES INVESTMENT FUND PTE 
LTD
			
		 	By:	 	 /s/ Chu Swee Yeok

			
		 	Name:	 	 Chu Swee Yeok

			
		 	Title:	 	 Director

		
		 	SINGAPORE BIO-INNOVATIONS PTE LTD
			
		 	By:	 	 /s/ Eugene Khoo Kay Jin

			
		 	Name:	 	 Eugene Khoo Kay Jin

			
		 	Title:	 	 Director

 [Amendment No. 2 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 FLUIDIGM CORPORATION 

AMENDMENT NO. 3 
 TO NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This Amendment
No. 3 (this “Amendment”) to that certain Ninth Amended and Restated Investor Rights Agreement, dated as of November 16, 2009 (the “Rights Agreement”), as amended on June 2, 2010 and as amended on
August 16, 2010, by and among Fluidigm Corporation, a Delaware corporation (the “Company”), and the Investors and Founders named therein is entered into effective as of January 6, 2011, by and among the Company and the
undersigned Investors constituting the Holders of at least two-thirds ( 2/3) of the outstanding shares of the Registrable Securities now held by all Holders (assuming the exercise or conversion of all outstanding Eligible Securities). Capitalized terms not defined herein have
the meanings set forth in the Rights Agreement. 
 RECITALS 

WHEREAS, on January 6, 2011, the Company sold and issued subordinated secured promissory notes (“Notes”) in
the aggregate principal amount of up to $5,000,000, together with related warrants to acquire shares of the Company’s Series E-1 preferred stock (“Warrants”) to certain existing investors in the Company pursuant to that certain
Note and Warrant Purchase Agreement dated January 6, 2011 (the “Bridge Financing”); 
 WHEREAS,
pursuant to the terms of the Bridge Financing, the Company and the undersigned stockholders desire that the holders of Series E-1 preferred stock issued upon exercise of the Warrants shall have the same rights as Holders (as defined in the Rights
Agreements), including registration rights, as the Company’s other preferred stock set forth in the Rights Agreement; 

WHEREAS, pursuant to Section 6.7 of the Rights Agreement, the Rights Agreement may be amended with the written consent of the
Company and Holders of at least two-thirds ( 2/3) of
the outstanding shares of the Registrable Securities then held by Holders (assuming the exercise or conversion of all outstanding Eligible Securities) (the “Requisite Holders”); and 

WHEREAS, the Company and the undersigned Investors constituting the Requisite Holders desire to amend the Rights Agreement to provide for
the foregoing changes. 
 NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually agree as follows: 

 AGREEMENT 
 1.  Amendment and Restatement of “Eligible Securities” Definition.  The definition of “Eligible Securities” set forth in Section 1.1 is hereby amended
and restated in its entirety as follows: 
 ““Eligible Securities” shall mean: 

(i)    the Series A Preferred Stock issued pursuant to the Series A Preferred Stock
Purchase Agreement dated December 1, 1999; 
 (ii)   the Series B Preferred Stock
issued pursuant to the Series B Preferred Stock Purchase Agreement dated July 5, 2000; 

(iii)  the Series C Preferred Stock issued pursuant to the Series C Preferred Stock Purchase
Agreement dated October 23, 2001; 
 (iv)   the Series C Preferred Stock issued pursuant to
the Series C Preferred Stock Purchase Agreement dated November 1, 2002; 
 (v)  the Series C
Preferred Stock issued pursuant to the Series C Preferred Stock and Warrant Purchase Agreement dated September 22, 2003; 
 (vi) the Series D Preferred Stock issued pursuant to the Series D Preferred Stock Purchase Agreement dated December 18, 2003; 

(vii) the Series D Preferred Stock issued pursuant to the Series D Preferred Stock Purchase Agreement dated
August 16, 2005; 
 (viii) the Series D Preferred Stock issued upon conversion of convertible promissory
note(s) issued pursuant to the Convertible Promissory Note Purchase Agreement (the “CNPA”) dated December 18, 2003, as amended by Amendment No. 1 to Convertible Note Purchase Agreement dated December 17, 2004,
between the Company and Biomedical Sciences Investment Fund Pte Ltd (the “BMSIF”); 

(ix)  the Series D Preferred Stock issued upon conversion of convertible promissory note(s) issued in
connection with the Convertible Note Agreement (the “CNA”) dated December 18, 2003, between the Company and Invus, L.P. (the “Invus”); 

(x)   the Series E Preferred Stock issued pursuant to the Series E Preferred Stock Purchase
Agreement dated June 13, 2006, as amended (the “Prior Purchase Agreement”); 

(xi)  the Series E Preferred Stock issued pursuant to the 2009 Purchase Agreement; 

 (xii) the Series D-1 Preferred Stock and the Series E-1 Preferred Stock
issued upon exercise of the Amended Eligible Warrants, as applicable, pursuant to and in accordance with the Offer; 
 (xiii) the Series E-1 Preferred Stock issued upon exercise of those certain warrants issued pursuant to the Note and Warrant Purchase Agreement dated January 6, 2011, 

(xiv) all Securities acquired by any Investor pursuant to the rights of first offer described in Sections 3 or 4 of this
Agreement; and 
 (xv) any Securities issued with respect to the foregoing upon any stock split, stock dividend,
recapitalization, or similar event or upon any exercise or conversion, as applicable.” 
 2.  Amendment and
Restatement of “Shadow Preferred Stock” Definition. The definition of “Shadow Preferred Stock” set forth in Section 1.1 is hereby amended and restated in its entirety as follows: 

““Shadow Preferred Stock” shall mean that certain series of the Company’s preferred stock
having the same rights, preferences and privileges as the original series of preferred stock issuable upon exercise of the Eligible Warrant, except that the original issuance price and liquidation preference of such series of preferred stock shall
be $7.00. Such Shadow Preferred Stock shall consist of “Series D-1 Preferred Stock” and “Series E-1 Preferred Stock,” as applicable.” 
 3.  Waiver of Right of First Offer.  The undersigned Holders of at least two-thirds
( 2/3) of the outstanding shares of the Registrable
Securities now held by all Holders hereby waive on behalf of all Investors any rights of participation or notice under Section 3 of the Rights Agreement, as amended, with respect to the securities sold pursuant to the Bridge Financing. By its
execution below, Lighthouse waives any right of participation or notice under Section 3 of the Rights Agreement, as amended from time to time, with respect to securities sold pursuant to the Bridge Financing. 

4.      Governing Law.  This Amendment shall be construed in accordance with, and governed
in all respects by, the laws of the State of California, as applied to agreements entered into, and to be performed entirely in such state, between residents of such state. 
 5.  Rights Agreement.  Wherever necessary, all other terms of the Rights Agreement are hereby amended to be consistent with the terms of this Amendment. Except as specifically
set forth herein, the Rights Agreement shall remain in full force and effect 
 6.  Counterparts. This
Amendment may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	COMPANY:	 	FLUIDIGM CORPORATION,
		 	a Delaware corporation
			
		 	By:	 	 /s/ Gajus Worthington

		 		 	Gajus Worthington,
		 		 	President and Chief Executive Officer

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above
written. 
  

					
	FOUNDERS:	 		 	
			
		 	  /s/ Gajus V. Worthington
	 	
		 	Gajus V. Worthington	 	
			
		 	 /s/ Stephen R. Quake
	 	
		 	Stephen R. Quake	 	

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	ALLIANCEBERNSTEIN VENTURE FUND I, L.P.
			
		 	By:	 	 AllianceBernstein ESG Venture Management,
 L.P., its general partner

			
		 	By:	 	 AllianceBernstein Global Derivatives
 Corporation, its general partner

				
		 	By:	 	 /s/ Amy Raskin
	 	
				
		 	Name:	 	 Amy Raskin
	 	
				
		 	Title:	 	 Senior Vice President
	 	

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	ALLOY VENTURES 2005, L.P.	 	
				
		 	By:	 	 Alloy Ventures 2005, LLC

its General Partner
	 	
				
		 	By:	 	 /s/ [illegible]
	 	
				
		 	Name:	 	  
	 	
			
		 	Title:	 	Managing Member of Alloy Ventures 2005 LLC General Partner of Alloy Ventures 2005, L.P.
		
		 	ALLOY VENTURES 2002, L.P.
		 	ALLOY PARTNERS 2002, L.P.
				
		 	By:	 	 Alloy Ventures 2002, LLC

its General Partner
	 	
				
		 	By:	 	 /s/ [illegible]
	 	
				
		 	Name:	 	  
	 	
			
		 	Title:	 	Managing Member of Alloy Ventures 2002 LLC General Partner of Alloy Partners 2002, L.P. and Alloy Ventures 2002, L.P.

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	VERSANT AFFILIATES FUND 1-A, L.P.	 	
		 	VERSANT AFFILIATES FUND 1-B, L.P.	 	
		 	VERSANT SIDE FUND I, L.P.	 	
		 	VERSANT VENTURE CAPITAL I, L.P.	 	
				
		 	By:	 	 Versant Ventures I, LLC
 its
General Partner
	 	
				
		 	By:	 	 /s/ Samuel D. Colella
	 	
				
		 	Name:	 	 Samuel D. Colella
	 	
				
		 	Title:	 	 Managing Director
	 	

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	LEHMAN BROTHERS HEALTHCARE VENTURE CAPITAL L.P.
				
		 	By:	 	 Lehman Brothers HealthCare Venture
 Capital Associates L.P.,
 its General Partner
	 	
				
		 	By:	 	 LB I Group Inc.,
 its
General Partner
	 	
				
		 	By:	 	 /s/ Ashvin Rao
	 	
				
		 	Name:	 	 Ashvin Rao
	 	
				
		 	Title:	 	 Vice President
	 	
		
		 	 LEHMAN BROTHERS P.A. LLC

				
		 	By:	 	 /s/ Ashvin Rao
	 	
				
		 	Name:	 	 Ashvin Rao
	 	
				
		 	Title:	 	 Vice President
	 	

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	LEHMAN BROTHERS PARTNERSHIP ACCOUNT 2000/2001, L.P.
				
		 	By:	 	 LB I Group Inc.,
 its
General Partner
	 	
				
		 	By:	 	 /s/ Ashvin Rao
	 	
				
		 	Name:	 	 Ashvin Rao
	 	
				
		 	Title:	 	 Vice President
	 	
		
		 	LEHMAN BROTHERS OFFSHORE PARTNERSHIP ACCOUNT 2000/2001, L.P.
				
		 	By:	 	 LB I Offshore Partners Group Ltd.,
 its General Partner
	 	
				
		 	By:	 	 /s/ Ashvin Rao
	 	
				
		 	Name:	 	 Ashvin Rao
	 	
				
		 	Title:	 	 Vice President
	 	

  
 [Amendment
No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	EUCLIDSR PARTNERS, L.P.	 	
				
		 	By:	 	 EuclidSR Associates, L.P.,
 its
General Partner
	 	
				
		 	By:	 	 /s/ Raymond J. Whitaker
	 	
				
		 	Name:	 	 Raymond J. Whitaker
	 	
				
		 	Title:	 	 General Partner
	 	
			
		 	EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.	 	
				
		 	By:	 	 EuclidSR Biotechnology Associates, L.P.,
 its General Partner
	 	
				
		 	By:	 	 /s/ Raymond J. Whitaker
	 	
				
		 	Name:	 	 Raymond J. Whitaker
	 	
				
		 	Title:	 	 General Partner
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 	INTERWEST PARTNERS VII, L.P.	 	
				
		 	By:	 	 InterWest Management Partners VII, LLC,
 its General Partner
	 	
				
		 	By:	 	 /s/ Michael Sweeney
	 	
				
		 	Name:	 	 Michael Sweeney
	 	
				
		 	Title:	 	 As agent for general partner
	 	
			
		 	INTERWEST INVESTORS VII, L.P.	 	
				
		 	By:	 	 InterWest Management Partners VII, LLC,
 its General Partner
	 	
				
		 	By:	 	 /s/ Michael Sweeney
	 	
				
		 	Name:	 	 Michael Sweeney
	 	
				
		 	Title:	 	 As agent for general partner
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 	LILLY BIOVENTURES, ELI LILLY & COMPANY	 	
				
		 	By:	 	 /s/ S. Edward Torres
	 	
				
		 	Name:	 	 S. Edward Torres
	 	
				
		 	Title:	 	 Managing Director
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 		 	
			
		 	 /s/ Bruce Burrows
	 	
		 	 BRUCE BURROWS
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 	 SMALLCAP WORLD FUND, INC.
	 	
				
		 	By:	 	 Capital Research and Management Company, its investment adviser
	 	
				
		 	By:	 	 /s/ Michael J. Downer
	 	
				
		 	Name:	 	 Michael J. Downer
	 	
				
		 	Title:	 	 Senior Vice President and Secretary
	 	

  

											
		 	 Approved for Signature
  

by CRMC Legal Dept.
	 		  	  
 WRB  
	 		 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 	FIDELITY CONTRAFUND:	 	
		 	FIDELITY ADVISOR NEW INSIGHTS FUND	 	
				
		 	By:	 	 /s/ Gary Ryan
	 	
				
		 	Name:	 	 Gary Ryan
	 	
				
		 	Title:	 	 Assistant Treasurer
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 	 FIDELITY CONTRAFUND: FIDELITY

CONTRAFUND
	 	
				
		 	By:	 	 /s/ Gary Ryan
	 	
				
		 	Name:	 	 Gary Ryan
	 	
				
		 	Title:	 	 Assistant Treasurer
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS	 	VARIABLE INSURANCE PRODUCTS FUND II:	 	
		 	CONTRAFUND PORTFOLIO	 	
				
		 	By:	 	 /s/ Gary Ryan
	 	
				
		 	Name:	 	 Gary Ryan
	 	
				
		 	Title:	 	 Assistant Treasurer
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 		 		 	
		 	IN-Q-TEL, INC.	 	
				
		 	By:	 	 /s/ Matt Strottman
	 	
				
		 	Name:	 	 Matt Strottman
	 	
				
		 	Title:	 	 Chief Financial Officer
	 	
			
		 	IN-Q-TEL EMPLOYEES FUND, LLC	 	
				
		 	By:	 	 /s/ Matt Strottman
	 	
				
		 	Name:	 	 Matt Strottman
	 	
				
		 	Title:	 	 CFO of In-Q-Tel, Inc., the manager of the Fund.
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	INVESTORS:	 	CROSS CREEK CAPITAL, L.P.	 	
				
		 	By:	 	 Cross Creek Capital GP, L.P.,

its Sole General Partner
	 	
				
		 	By:	 	 Cross Creek Capital, LLC,

its Sole General Partner
	 	
				
		 	By:	 	 Wasatch Advisors, Inc.,
 its
Sole Member
	 	
				
		 	By:	 	 /s/ Daniel Thurber
	 	
				
		 	Name:	 	 Daniel Thurber
	 	
				
		 	Title:	 	 Vice President
	 	
			
	INVESTORS:	 	CROSS CREEK CAPITAL EMPLOYEES’ FUND, L.P. 	 	
				
		 	By:	 	 Cross Creek Capital GP, L.P.,

its Sole General Partner
	 	
				
		 	By:	 	 Cross Creek Capital, LLC,

its Sole General Partner
	 	
				
		 	By:	 	 Wasatch Advisors, Inc.,
 its
Sole Member
	 	
				
		 	By:	 	 /s/ Daniel Thurber
	 	
				
		 	Name:	 	 Daniel Thurber
	 	
				
		 	Title:	 	 Vice President
	 	

  

[Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	WASATCH FUNDS, INC.	 	
		 	Wasatch Small Cap Growth Fund	 	
				
		 	By:	 	 Wasatch Advisors, Inc.,
 its
Investment Adviser
	 	
				
		 	By:	 	 /s/ Daniel Thurber
	 	
				
		 	Name:	 	 Daniel Thurber
	 	
				
		 	Title:	 	 Vice President
	 	

  

[Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	SIGHTLINE HEALTHCARE FUND III, L.P.
				
		 	By:	 	 /s/ [illegible]
	 	
				
		 	Name:	 	  
	 	
				
		 	Title:	 	 Managing Director
	 	

  

[Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

  

							
	INVESTORS:	 	 Alfred J. Mandel
	 	
				
		 	By:	 	 /s/ Alfred J. Mandel
	 	
				
		 	Name:	 	 Alfred J. Mandel
	 	
				
		 	Title:	 	  
	 	

  

[Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm Corporation] 

							
	 INVESTORS:
	 	 LEO J. PARRY, JR. AND ROBERTA J.
PARRY TTEES PARRY FAMILY REVOCABLE TRUST
 DTD
01/22/97
	 	
				
		 	By:	 	 /s/ Leo J. Parry
	 	
				
		 	Name:	 	 Leo J. Parry
	 	
				
		 	Title:	 	 Trustee
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

							
	 INVESTORS:
	 	HENRY P. MASSEY, JR. TTEE MASSEY FAMILY TRUST
U/A DTD 7/06/88	 	
				
		 	By:	 	 /s/ Henry P. Massey Jr.
	 	
				
		 	Name:	 	 Henry P. Massey Jr.
	 	
				
		 	Title:	 	 Trustee
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

							
	 INVESTORS:
	 	 Thomas J. Parry
	 	
				
		 	By:	 	 /s/ Thomas J. Parry
	 	
				
		 	Name:	 	 Thomas J. Parry
	 	
				
		 	Title:	 	  
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

					
	 INVESTORS:
	 	
            /s/ John E. 
Strobeck
	 	
		 	            JOHN E. STROBECK PHD 
M.D. 12/30/10

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement
of Fluidigm Corporation] 

							
	 INVESTORS:
	 	ADVISORY TRUST COMPANY OF DELAWARE, CUSTODIAN FOR
SANDRA KAY ROTH IRA	 	
				
		 	By:	 	 /s/ Kathleen Parsons
	 	
				
		 	Name:	 	 Kathleen Parsons
	 	
				
		 	Title:	 	 Trust Administrator
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD
				
		 	By:	 	 /s/ Chu Swee Yeok
	 	
				
		 	Name:	 	 Chu Swee Yeok
	 	
				
		 	Title:	 	 Director
	 	
			
	 INVESTORS:
	 	SINGAPORE BIO-INNOVATIONS PTE LTD 	 	
				
		 	By:	 	 /s/ Eugene Khoo Kay Jin
	 	
				
		 	Name:	 	 Eugene Khoo Kay Jin
	 	
				
		 	Title:	 	 Director
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	NR07, LLC	 	
				
		 	By:	 	 /s/ Sumner Rosenberg
	 	
				
		 	Name:	 	 Sumner Rosenberg
	 	
				
		 	Title:	 	 President/Manager
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	HEALTH CARE ADMINISTRATION COMPANY	 	
				
		 	By:	 	 /s/ Gary L. Bowers
	 	
				
		 	Name:	 	 Gary L. Bowers
	 	
				
		 	Title:	 	 President
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	JONATHAN S. HOOT AND ANDREA T. HOOT,
TRUSTEES OF
THE HOOT FAMILY REVOCABLE
TRUST DTD 3/16/99
				
		 	By:	 	 /s/ Jon Hoot
	 	
				
		 	Name:	 	 Jon Hoot
	 	
				
		 	Title:	 	 Trustee
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	 MICHAEL J. REARDON TRUST AGREEMENT

DATED JUNE 5, 1996
	 	
				
		 	By:	 	 /s/ Michael J. Reardon
	 	
				
		 	Name:	 	 Michael J. Reardon
	 	
				
		 	Title:	 	 Trustee
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	 Gary R. Bang
	 	
				
		 	By:	 	 /s/ Gary R Bang
	 	
				
		 	Name:	 	  
	 	
				
		 	Title:	 	  
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	TTC FUND 1B TRUST	 	
				
		 	By:	 	 /s/ Philip H. Albert
	 	
				
		 	Name:	 	 Philip H. Albert
	 	
				
		 	Title:	 	 Trustee
	 	
			
		 	12/29/2010	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of Fluidigm
Corporation] 

  

							
	 INVESTORS:
	 	FREDRICK H. STERN	 	
				
		 	By:	 	 /s/ Fredrick H. Stern
	 	
				
		 	Name:	 	 Fredrick H. Stern
	 	
				
		 	Title:	 	  
	 	

 [Amendment No. 3 to Ninth Amended and Restated Investor Rights Agreement of
Fluidigm Corporation]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]